var title_f41_0_41984="Lidocaine: Patient drug information";
var content_f41_0_41984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/39/12915?source=see_link\">",
"       Lidocaine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/58/36772?source=see_link\">",
"       Lidocaine (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/46/29413?source=see_link\">",
"       Lidocaine (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11385 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41984=[""].join("\n");
var outline_f41_0_41984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/39/12915?source=related_link\">",
"      Lidocaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/58/36772?source=related_link\">",
"      Lidocaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/46/29413?source=related_link\">",
"      Lidocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41985="Henoch Schonlein PI";
var content_f41_0_41985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Rash in a person with Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Kim, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41985=[""].join("\n");
var outline_f41_0_41985=null;
var title_f41_0_41986="Clinical findings M pneumoniae";
var content_f41_0_41986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Chronology of untreated Mycoplasma pneumoniae pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The horizontal dimension depicts the estimated duration of symptoms, signs, positive cultures of respiratory tract samples, and radiographic abnormalities. The temporal correlations of these features are shown vertically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971; 123:74, by permission of Oxford University Press. Copyright &copy; 1971.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41986=[""].join("\n");
var outline_f41_0_41986=null;
var title_f41_0_41987="Follicular miniaturization in androgenetic alopecia";
var content_f41_0_41987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Follicular miniaturization in androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair follicle miniaturization viewed through a dermatoscope. Progressive reduction in hair follicle caliber is an important feature of androgenetic alopecia. A mixture of normal and miniaturized hairs is present in this patient with androgenetic alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41987=[""].join("\n");
var outline_f41_0_41987=null;
var title_f41_0_41988="Reciprocal serum creatinine concentration and chronic kidney disease";
var content_f41_0_41988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reciprocal serum creatinine concentration and chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41988/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/0/41988/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the creatinine clearance to estimate glomerular filtration rate (GFR) is based on the fact that creatinine is freely filtered and not reabsorbed. Thus, if creatinine secretion is ignored, all of the filtered creatinine (equal to the product of the GFR and the serum creatinine concentration [SCr]) is equal to all of the excreted creatinine (equal to product of the urine creatinine concentration [UCr] and the urine flow rate). Thus:",
"   </p>",
"   <p>",
"    GFR &nbsp;x &nbsp;SCr &nbsp;= &nbsp;UCr &nbsp;x &nbsp;V",
"   </p>",
"   <p>",
"    GFR &nbsp;= &nbsp;[UCr &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     V]/SCr",
"    </span>",
"   </p>",
"   <p>",
"    If muscle mass remains constant, then creatinine production and therefore creatinine excretion (UCr &nbsp;x &nbsp;V) will be relatively constant. Thus, the last equation can be simplified to the GFR being directly proportional to the reciprocal of the serum creatinine concentration. In the clinic, monitoring the reciprocal serum creatinine concentration over time is an effective means of evaluating temporal changes in renal function.",
"   </p>",
"   <p>",
"    The methods required to use the reciprocal serum creatinine concentration to follow changes in renal function over time will be reviewed here. A graph is also provided to help the clinician in performing this task. A detailed discussion of the use of the serum creatinine concentration and the creatinine clearance to estimate GFR, including drugs that interfere with either creatinine secretion or the assay used to measure the serum creatinine, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the decline of renal function over time is important for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of progression of renal failure can be determined. In many cases, this can help predict an approximate time interval when renal replacement will be required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The effects of treatment on the rate of decline of renal function can be monitored. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deviation from a chronic rate of progression can be detected. In particular, an accelerated rate of progression may represent a superimposed and often reversible problem such as volume depletion.",
"     </li>",
"     <li>",
"      In clinical trials, one can compare the rates of decline for groups of patients and the effect of a new treatment on the rate of decline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF GLOMERULAR FILTRATION RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal method for following the functional decline of the glomerular filtration rate (GFR) over time depends upon the reasons for which renal functional decline is being monitored. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .) The principal settings are within clinical trials and in the clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;For clinical trials, which require the most accurate determination of the glomerular filtration rate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-four hour urine collections for creatinine and urea are not optimal because it is difficult to ensure a complete collection and because creatinine clearance overestimates the GFR due to tubular secretion of creatinine and urea clearance underestimates the GFR due to tubular reabsorption.",
"     </li>",
"     <li>",
"      Monitoring the decline of the reciprocal serum creatinine is also not sufficiently accurate, since the serum creatinine does not necessarily correlate with the GFR due to factors such as tubular secretion of creatinine and changes in muscle mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in clinical trials, the glomerular filtrate rate should be determined by measurement of the clearance of inulin or a radiolabeled compound such as iothalamate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the radioisotopes undergo a small degree of tubular secretion, the GFR is only underestimated by a few",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinic, clinicians require a less expensive and less time-consuming test than the measurement of inulin or iothalamate clearances. In addition, although the results should be accurate, they do not need to be as precise as those required for a clinical trial. Many trials enroll and focus upon patients with relatively well-preserved renal function, a setting in which it is difficult to detect small changes in function over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the clinic patient is followed over a longer time interval and frequently has moderate loss of renal function. In this setting, renal function assessment can be performed via 24-hour urine collections for creatinine and urea, serial measurements of the serum creatinine concentration, or the use of the reciprocal serum creatinine concentration curve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Creatinine clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advantage of the 24-hour clearance is that urea excretion, creatinine excretion, and serum determinations of urea and creatinine are each determined. One can then calculate the creatinine or urea clearance based entirely upon these measured values. In addition, the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and an estimate of dietary protein intake can be determined based on urinary urea nitrogen excretion (nPNA) in the stable patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some disadvantages of the 24-hour collection are that it is time consuming and cumbersome for the patient, cannot always be obtained, and is frequently incomplete. The use of 24-hour collections for creatinine clearance has markedly decreased due to the widespread use of formulas that estimate GFR from serum creatinine. However, these collections may still be useful in patients who have large muscle mass or a marked decrease in muscle mass. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serum creatinine concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If muscle mass is relatively stable, a rising serum creatinine concentration implies that the GFR is worsening, a falling serum creatinine indicates improvement, and a stable value usually reflects stable disease. An important caveat is that a relatively stable serum creatinine concentration in the normal or near-normal range does not necessarily imply that the disease is stable. The relationship between the serum creatinine concentration and GFR predicts that initial reductions in GFR produce relatively small increases in the serum creatinine concentration (",
"    <a class=\"graphic graphic_figure graphicRef74963 \" href=\"mobipreview.htm?25/11/25790\">",
"     figure 1",
"    </a>",
"    ). In such patients, a seemingly small elevation in serum creatinine (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 9 to 18",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    may reflect a relatively large loss of renal function. Furthermore, the elevation in serum creatinine may be blunted by an increase in proximal tubular creatinine secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, most laboratories are now reporting estimated glomerular filtration rate (eGFR) when the serum creatinine is measured; eGFR is now the most commonly used method to follow kidney function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3967473\">",
"    <span class=\"h3\">",
"     Serum cystatin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum cystatin C may be a better marker of kidney functional decline than serum creatinine. However, this test is not generally used for clinical evaluation of kidney function because the serum creatinine is included in automated chemistry panels, and the serum cystatin C is more costly. In addition, measurement of cystatin C has not had national standardization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H23#H23\">",
"     \"Assessment of kidney function\", section on 'Serum cystatin C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Reciprocal serum creatinine concentration curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because GFR is inversely proportional to the serum creatinine, the reciprocal serum creatinine curve has been used to follow changes in the renal function of patients with chronic kidney disease. This concept was first established by Walser and Mitch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Since the GFR varies inversely with the reciprocal of the serum creatinine concentration",
"    <span class=\"nowrap\">",
"     (1/SCr),",
"    </span>",
"    a graph of",
"    <span class=\"nowrap\">",
"     1/SCr",
"    </span>",
"    plotted against time is expected to be linear in a patient who has a constant linear decline in renal function and in whom creatinine generation minus extrarenal creatinine elimination and tubular secretion of creatinine remains constant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. If this is the case, then",
"    <span class=\"nowrap\">",
"     1/SCr",
"    </span>",
"    can be followed as an aid in predicting the future decline of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several caveats in following the reciprocal serum creatinine over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients do not have a consistent linear decline in renal function over time. However, this will be recognized from the graph.",
"     </li>",
"     <li>",
"      As mentioned above, there is a large change in magnitude of the GFR and therefore the reciprocal serum creatinine, with small changes in serum creatinine in patients with relatively normal renal function. Thus, plotting the reciprocal serum creatinine is not useful until the serum creatinine is above 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some experts do not believe that following the reciprocal creatinine over time is useful because of variations in extrarenal creatinine degradation, tubular secretion, and creatinine production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reciprocal creatinine curve provides information on the change in renal function over time. However, it does not necessarily predict when renal replacement therapy will occur, because different patients may experience symptoms of uremia at different times.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plotting the reciprocal serum creatinine over time is cumbersome to do both on graph paper and computer, which may not be available when one examines the patient or obtains laboratory values.",
"   </p>",
"   <p>",
"    The following graphs, using conventional units and international units, have been designed to overcome these difficulties (",
"    <a class=\"graphic graphic_figure graphicRef75944 \" href=\"mobipreview.htm?15/55/16247\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54861 \" href=\"mobipreview.htm?2/2/2090\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41988/abstract/10\">",
"     10",
"    </a>",
"    ]. The graph has a reciprocal serum creatinine on the ordinate, and the abscissa has a scale divided into 12 months, with each bold division representing the start of a new year. These graphs may be printed out and placed in the charts of patients, and the serum creatinine may then be penciled in.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Graphing renal function over time with estimation equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option is to graph changes in renal function over time by calculating the GFR using an estimating equation and then producing a graph of the estimated GFR versus time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2752860\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If creatinine secretion is ignored and muscle mass remains constant, then glomerular filtration rate (GFR) is directly proportional to the reciprocal of the serum creatinine concentration. Monitoring the reciprocal serum creatinine concentration over time can be used to evaluate temporal changes in renal function in an individual. The following graphs, using conventional units and international units, may be printed and used to plot the reciprocal creatinine curve (",
"      <a class=\"graphic graphic_figure graphicRef75944 \" href=\"mobipreview.htm?15/55/16247\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54861 \" href=\"mobipreview.htm?2/2/2090\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Reciprocal serum creatinine concentration curve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A graph of",
"      <span class=\"nowrap\">",
"       1/SCr",
"      </span>",
"      plotted against time is expected to be linear in a patient who has a constant linear decline in renal function. If this is the case, then",
"      <span class=\"nowrap\">",
"       1/SCr",
"      </span>",
"      can be followed as an aid in predicting the future decline of renal function. However, a large change in GFR may result in only a small change in serum creatinine, and therefore in",
"      <span class=\"nowrap\">",
"       1/SCr,",
"      </span>",
"      in patients who have relatively normal renal function. Thus, plotting the reciprocal serum creatinine is not useful until the serum creatinine is above 2.5",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      In addition, the reciprocal creatinine curve may be misleading if there are variations in extrarenal creatinine degradation, tubular secretion, and creatinine production (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Reciprocal serum creatinine concentration curve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively, estimated GFR using equations that estimate GFR from the serum creatinine and other variables can be plotted over time. Websites are currently available to aid in the calculation of the GFR through these formulas, such as",
"      <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm\">",
"       www.kidney.org/professionals/kdoqi/gfr_calculator.cfm",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Graphing renal function over time with estimation equations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/1\">",
"      Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/2\">",
"      Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/3\">",
"      Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002; 39:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/4\">",
"      Kopple JD, Gao XL, Qing DP. Dietary protein, urea nitrogen appearance and total nitrogen appearance in chronic renal failure and CAPD patients. Kidney Int 1997; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/5\">",
"      Fesler P, Mimran A. Estimation of glomerular filtration rate: what are the pitfalls? Curr Hypertens Rep 2011; 13:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/6\">",
"      Mitch WE, Walser M, Buffington GA, Lemann J Jr. A simple method of estimating progression of chronic renal failure. Lancet 1976; 2:1326.",
"     </a>",
"    </li>",
"    <li>",
"     Mitch, WE. Measuring the rate of progression of renal insufficiency. In: Contemporary issues in Nephrology 14: Progressive nature of renal diseases, Mitch, WE, Brenner, BM, Stein, JH (Eds), Churchill Livingstone, New York 1986, p. 167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/8\">",
"      Rutherford WE, Blondin J, Miller JP, et al. Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int 1977; 11:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/9\">",
"      Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 1983; 74:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41988/abstract/10\">",
"      Bleyer AJ. A reciprocal graph to plot the reciprocal serum creatinine over time. Am J Kidney Dis 1999; 34:576.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2362 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41988=[""].join("\n");
var outline_f41_0_41988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2752860\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT OF GLOMERULAR FILTRATION RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3967473\">",
"      - Serum cystatin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Reciprocal serum creatinine concentration curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Graphing renal function over time with estimation equations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2752860\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2362|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/11/25790\" title=\"figure 1\">",
"      GFR and plasma creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/55/16247\" title=\"figure 2\">",
"      Reciprocal creatinine graph mg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/2/2090\" title=\"figure 3\">",
"      Reciprocal creatinine graph SI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41989="Mesna: Drug information";
var content_f41_0_41989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mesna: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/34/34340?source=see_link\">",
"    see \"Mesna: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/22/44388?source=see_link\">",
"    see \"Mesna: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mesnex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mesna for injection;",
"     </li>",
"     <li>",
"      Uromitexan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Uroprotectant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Details concerning dosing in combination regimens should also be consulted. Mesna dosing schedule should be repeated each day ifosfamide is received. If ifosfamide dose is adjusted, the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of ifosfamide-induced hemorrhagic cystitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short infusion standard-dose ifosfamide (&lt;2.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day): Mesna dose is equal to 60% of the ifosfamide dose given in 3 divided doses (0, 4, and 8 hours after the start of ifosfamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion standard-dose ifosfamide (&lt;2.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day): ASCO guidelines: Mesna dose (as an I.V. bolus) is equal to 20% of the ifosfamide dose, followed by a continuous infusion of mesna at 40% of the ifosfamide dose, continue mesna infusion for 12-24 hours after completion of ifosfamide infusion (Hensley, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose ifosfamide (&gt;2.5 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day): ASCO guidelines: Evidence for use is inadequate; more frequent and prolonged mesna administration regimens may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. followed by oral (for ifosfamide doses &le;2 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day): Mesna dose is equal to 100% of the ifosfamide dose, given as 20% of the ifosfamide dose I.V. at hour 0, followed by 40% of the ifosfamide dose given orally 2- and 6 hours after start of ifosfamide",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/22/44388?source=see_link\">",
"      see \"Mesna: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mesnex&reg;: 100 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mesnex&reg;: 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13226757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mesna for injection: 100 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer orally in tablet formulation or parenteral solution diluted in water, milk, juice, or carbonated beverages; patients who vomit within 2 hours after taking oral mesna should repeat the dose or receive I.V. mesna",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer by short (15-30 minutes) infusion or continuous infusion (maintain continuous infusion for 12-24 after completion of ifosfamide infusion) (Hensley, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F193557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, cefepime, cladribine, docetaxel, doxorubicin liposome, etoposide phosphate, filgrastim, fludarabine, gallium nitrate, gemcitabine, granisetron, linezolid, melphalan, methotrexate, micafungin, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, sargramostim, sodium bicarbonate, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ifosfamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ifosfamide/epirubicin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preventative agent  to reduce the incidence of ifosfamide-induced hemorrhagic cystitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F193548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preventative agent  to reduce the incidence of cyclophosphamide-induced hemorrhagic cystitis with high-dose cyclophosphamide",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesna alone (frequency not defined):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, hyperesthesia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, flatulence, nausea, taste alteration/bad taste (with oral administration), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular: Arthralgia, back pain, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mesna alone or in combination: Postmarketing and/or case reports: Allergic reaction, anaphylactic reaction, hypersensitivity, hyper-/hypotension, injection site erythema, injection site pain, limb pain, malaise, myalgia, platelets decreased, ST-segment increased, tachycardia, tachypnea, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mesna or other thiol compounds, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions have been reported; symptoms ranged from mild hypersensitivity to systemic anaphylactic reactions and may include fever, hypotension, and/or tachycardia. Patients with autoimmune disorders receiving cyclophosphamide and mesna may be at increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematuria: Examine morning urine specimen for hematuria prior to ifosfamide or cyclophosphamide treatment; if hematuria (&gt;50 RBC/HPF) develops, reduce the ifosfamide/cyclophosphamide dose or discontinue the drug; will not prevent hemorrhagic cystitis in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ifosfamide/cyclophosphamide toxicities: Will not prevent or alleviate toxicities associated with ifosfamide or cyclophosphamide, other than hemorrhagic cystitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Mesna will not reduce the risk of thrombocytopenia-related hematuria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: I.V. formulation contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydration: Patients should receive adequate hydration during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6841638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mesna Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $61.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mesnex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $39.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mesnex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (10): $943.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Delinar (AR);",
"     </li>",
"     <li>",
"      Mescryo (MX);",
"     </li>",
"     <li>",
"      Mesnil (MX, PE, PY);",
"     </li>",
"     <li>",
"      Mesodal (MX);",
"     </li>",
"     <li>",
"      Mistabron (KP, LU, PH);",
"     </li>",
"     <li>",
"      Mitexan (BR);",
"     </li>",
"     <li>",
"      Mucofluid (ES);",
"     </li>",
"     <li>",
"      Uromitexan (AT, AU, BE, BG, CH, CL, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IN, IT, KP, LU, MT, NL, NO, NZ, PK, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Uroprot (MX, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In blood, mesna is oxidized to dimesna which in turn is reduced in the kidney back to mesna, supplying a free thiol group which binds to and inactivates acrolein, the urotoxic metabolite of ifosfamide and cyclophosphamide",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: No tissue penetration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 69% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly oxidized intravascularly to mesna disulfide (dimesna); dimesna is reduced in renal tubules back to mesna following glomerular filtration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 45% to 79%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Mesna: ~22 minutes; Dimesna: ~70 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. followed by oral: 1-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (18% to 32% as mesna; 33% as dimesna)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ben Yehuda A, Heyman A and Steiner Salz D, &ldquo;False Positive Reaction for Urinary Ketones With Mesna,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(6):547-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/3111808/pubmed\" id=\"3111808\" target=\"_blank\">",
"        3111808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brock N and Pohl J, &ldquo;The Development of Mesna for Regional Detoxification,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1983, 10(Suppl A):33-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/6414694/pubmed\" id=\"6414694\" target=\"_blank\">",
"        6414694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Cancer Chemotherapy,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1989, 31(793):49-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/2725418/pubmed\" id=\"2725418\" target=\"_blank\">",
"        2725418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goren MP, &ldquo;Oral Administration of Mesna With Ifosfamide,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1996, 23(3 Suppl 6):91-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goren MP, &ldquo;Oral Mesna: A Review,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1992, 19(6 Suppl 12):65-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 27(1):127-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/19018081/pubmed\" id=\"19018081\" target=\"_blank\">",
"        19018081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaw SL, Downie PA, Waters KD, et al, &ldquo;Adverse Hypersensitivity Reactions to Mesna as Adjunctive Therapy for Cyclophosphamide,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2007, 49(3):341-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/16333822/pubmed\" id=\"16333822\" target=\"_blank\">",
"        16333822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mace JR, Keohan ML, Bernardy H, et al, &ldquo;Crossover Randomized Comparison of Intravenous Versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated With High-Dose Ifosfamide,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2003, 9(16 Pt 1):5829-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/14676103/pubmed\" id=\"14676103\" target=\"_blank\">",
"        14676103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Menard C, Bourguignon C, Schlatter J, et al, &ldquo;Stability of Cyclophosphamide and Mesna Admixtures in Polyethylene Infusion Bags,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(12):1789-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/14632591/pubmed\" id=\"14632591\" target=\"_blank\">",
"        14632591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pohl J, &ldquo;Toxicology, Pharmacology, and Interactions of Sodium 2-Mercaptoethane Sulfonate (Mesna),&rdquo;",
"      <i>",
"       Curr Chemotherapy",
"      </i>",
"      , 1981, 2:1387-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schoenike SE and Dana WJ, &ldquo;Ifosfamide and Mesna,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1990, 9(3):179-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/2107997/pubmed\" id=\"2107997\" target=\"_blank\">",
"        2107997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuchter LM, Hensley ML, Meropol NJ, et al, &ldquo;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/12065567/pubmed\" id=\"12065567\" target=\"_blank\">",
"        12065567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu LL and Moore MJ, &ldquo;Use of Mesna to Prevent Ifosfamide-Induced Urotoxicity,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 1998, 6(2):144-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/0/41989/abstract-text/9540174/pubmed\" id=\"9540174\" target=\"_blank\">",
"        9540174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9615 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41989=[""].join("\n");
var outline_f41_0_41989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193507\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193552\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193510\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193531\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193511\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193483\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13226757\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193469\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193486\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193557\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193484\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193548\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193550\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193489\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193473\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299676\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193476\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193479\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193492\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193518\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6841638\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323377\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193481\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193493\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193472\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193488\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/34/34340?source=related_link\">",
"      Mesna: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/22/44388?source=related_link\">",
"      Mesna: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41990="Vaginal cuff dehiscence after hysterectomy";
var content_f41_0_41990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginal cuff dehiscence after hysterectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Hye-Chun Hur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41990/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/0/41990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal cuff dehiscence is a rare, but potentially morbid, complication of total hysterectomy (surgical removal of the uterus and cervix). After removal of the uterine specimen, the vaginal incision (vaginal cuff) or the peritoneal defect is closed. Vaginal cuff dehiscence refers to separation of the vaginal incision. The term vaginal cuff dehiscence is frequently interchanged with the terms cuff separation or cuff rupture. All denote the separation of a vaginal incision that was previously closed at time of initial hysterectomy.",
"   </p>",
"   <p>",
"    After dehiscence of the vaginal cuff, abdominal or pelvic contents may be expelled through the vaginal opening. Bowel evisceration can lead to serious sequelae, including peritonitis, bowel injury and necrosis, and sepsis. Prompt surgical and medical intervention is required.",
"   </p>",
"   <p>",
"    Incidence, risk factors, and management recommendations for vaginal dehiscence that occurs after total hysterectomy will be reviewed here. Other complications of gynecologic surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=see_link\">",
"     \"Complications of gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of vaginal cuff dehiscence following hysterectomy is approximately 0.24 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a large case series, there were 28 cases of vaginal cuff dehiscence among 11,606 patients (0.24 percent) who underwent total hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence of vaginal cuff dehiscence after any type of pelvic surgery is 0.03 percent and varies by surgical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of vaginal cuff dehiscence is higher after laparoscopic hysterectomy (0.7 to 1.4 percent) compared with abdominal (0.1 to 0.3 percent) or vaginal (0.1 to 0.3 percent) approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1-3,5-7\">",
"     1-3,5-7",
"    </a>",
"    ]. While there have been concerns about a markedly high rate of cuff dehiscence following laparoscopic hysterectomy (4.9 percent), a follow-up study suggests a lower dehiscence rate of 0.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true incidence of vaginal cuff dehiscence after hysterectomy is unknown since this complication is likely underreported. Also, patients with cuff dehiscences may present to a different physician or hospital than for the initial hysterectomy, thereby making data collection difficult. Further, case reports of vaginal cuff dehiscence generally do not include for comparison the number of hysterectomies that were NOT associated with this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal dehiscence is rare, thus it is difficult to establish predisposing factors. Prior studies have suggested different risk factors for vaginal dehiscence among postmenopausal women (eg, pelvic prolapse) versus premenopausal women (eg, coitus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,4,6,8-12\">",
"     1,2,4,6,8-12",
"    </a>",
"    ]. Although the risk factor profile seemingly varies with menopausal status, a true difference is difficult to determine because the menopausal status of women undergoing hysterectomy is not consistently reported in most studies.",
"   </p>",
"   <p>",
"    In general, cuff dehiscence is associated with risk factors for poor wound healing, excessive pressure at the vaginal incision site, or pelvic floor defects; however, some instances of vaginal cuff dehiscence occur spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,4,8\">",
"     1,2,4,8",
"    </a>",
"    ]. The following factors have been proposed, but have not been proven, as risk factors for vaginal cuff dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,4,8,9,13-15\">",
"     1,2,4,8,9,13-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaginal cuff cellulitis or abscess",
"     </li>",
"     <li>",
"      Vaginal trauma (eg, intercourse, instrumentation)",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Pelvic organ prolapse",
"     </li>",
"     <li>",
"      Vaginal hematoma",
"     </li>",
"     <li>",
"      Pelvic radiation therapy",
"     </li>",
"     <li>",
"      Postmenopausal status",
"     </li>",
"     <li>",
"      Chronic conditions that increase intraabdominal pressure (eg, obesity, cough, constipation)",
"     </li>",
"     <li>",
"      Impaired wound healing (eg, malnutrition, anemia, diabetes, immunosuppression)",
"     </li>",
"     <li>",
"      Mode of surgery (eg, total laparoscopic hysterectomy, robotic-assisted total laparoscopic hysterectomy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of laparoscopic hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of over 11,000 hysterectomies, total laparoscopic hysterectomy (vaginal incision and closure performed laparoscopically) had a higher incidence of dehiscence compared with the abdominal, vaginal, or laparoscopically-assisted approach (vaginal incision and closure performed transvaginally) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. While other studies have not found an association of a laparoscopic approach with dehiscence, these reports were not powered to do so; the studies were conducted earlier and contained a smaller portion of laparoscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unique features of laparoscopic surgery that potentially increase the risk of vaginal dehiscence are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of energy sources to make the vaginal colpotomy may result in tissue destruction beyond the incision, potentially increasing tissue necrosis and leading to poor healing of the vaginal cuff compared with a sharp colpotomy that is made using a scalpel or scissors. Different electrosurgical instruments (eg, bipolar and monopolar devices) or ultrasonic devices produce varying amounts of tissue destruction; however, there are limited data regarding the impact of electrosurgery on wound healing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of electrosurgery\", section on 'Thermal spread'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laparoscopic magnification of the surgical field may distort the view and cause the surgeon to place sutures too close to the vaginal cuff edge (&lt;1 cm) or not achieve full thickness closure.",
"     </li>",
"     <li>",
"      Laparoscopic suturing to close the vaginal cuff requires advanced training to achieve secure knots via extracorporeal or intracorporeal techniques. Inappropriate use of the laparoscopic knot pusher or poor intracorporeal knot tying technique may compromise suture integrity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures to minimize the risk of vaginal cuff dehiscence after hysterectomy are uncertain since the causes are not well-established. Strategies based on existing data are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609085\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risk of cuff cellulitis or abscess, preoperative testing can include evaluation and treatment for bacterial vaginosis or trichomonas vaginalis and cervical cultures for gonorrhea and chlamydia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. Perioperative antibiotic prophylaxis for hysterectomy patients also minimizes the risk of vaginal cuff infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link&amp;anchor=H17#H17\">",
"     \"Bacterial vaginosis\", section on 'Gynecologic procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link&amp;anchor=H5#H5\">",
"     \"Trichomonas vaginalis\", section on 'Consequences'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether variations in the surgical management of the vaginal cuff influence the risk of dehiscence.",
"   </p>",
"   <p>",
"    After total hysterectomy, the vaginal cuff can be sutured closed or left open. In the open technique, the peritoneal defect superior to the cuff is closed and edges of the vaginal cuff seal gradually via granulation. It does not appear that either technique is superior for preventing cuff dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link&amp;anchor=H29#H29\">",
"     \"Abdominal hysterectomy\", section on 'Treatment of the vaginal cuff'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since women undergoing total hysterectomy by laparoscopic techniques may be at greater risk for dehiscence compared with other approaches, we suggest the following precautions during this procedure (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimize tissue quality at the vaginal incision &mdash; Given the biologic concern that incisions made using an energy source may impair wound healing, we suggest that surgeons make the colpotomy with electrosurgical techniques that result in minimal thermal spread. Such techniques include: (1) minimizing tissue contact when using monopolar current (improves current density); (2) using pure cutting current (lower voltage) rather than coagulation current (higher voltage) to minimize tissue destruction; and (3) refraining from using energy sources to achieve hemostasis of every vaginal cuff vessel, especially those that can be made hemostatic with the vaginal cuff closure. Alternatively, non-electrosurgical energy devices that produce less tissue damage than monopolar and bipolar instruments (eg, harmonic scalpel, laparoscopic morcellating blade) can be used to make the colpotomy. If an energy source is used, care should be taken to limit the extent of tissue destruction.",
"      <br/>",
"      <br/>",
"      Excessive bleeding from the vaginal cuff is rarely a problem. If bleeding is encountered, it can often be controlled by suturing the vaginal cuff in a timely fashion or by applying an energy source to achieve hemostasis of specific vessels of the vaginal cuff that cause significant bleeding. This minimizes the amount of devascularized vaginal tissue, since such tissue may lead to poorer healing. Some surgeons inject a vasoconstrictor (eg, vasopressin) into the planned incision site before making the colpotomy in an attempt to minimize vaginal cuff bleeding.",
"      <br/>",
"      <br/>",
"      Upon cuff closure, the edges should be reapproximated, but not strangulated.",
"     </li>",
"     <li>",
"      Close the cuff securely &mdash; Use a delayed absorbable monofilament suture (eg, polydioxanone [PDS II&trade;]) rather than catgut. Although some surgeons use a delayed absorbable braided suture, we prefer a monofilament suture for the theoretical advantage of lower infectious risks. We recommend placing the suture at least 1 cm from the vaginal cuff edge. The closure should be full thickness, including the vaginal epithelium, vaginal musculature and the pubocervical fascial ring. Some data suggest less cuff dehiscence with closure of the vaginal cuff with barbed suture; however, the data are limited and further studies are needed to evaluate the impact of the type of suture used for vaginal cuff closure and risk of dehiscence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postoperative period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scar tissue attains about 40 percent of its final strength in the first postoperative month and strength continues to increase for as long as a year after injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, after total hysterectomy, women should maintain pelvic rest (defer vaginal intercourse and avoid placing objects into the vagina) and refrain from heavy lifting. In our practice, we advise patients to avoid these activities for six to eight weeks. Patients at high risk of dehiscence may be counseled to avoid these activities for an extended period (eg, 12 weeks), although there are no data to show that a prolonged period of pelvic rests decreases the risk of cuff dehiscence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=see_link&amp;anchor=H40#H40\">",
"     \"Abdominal hysterectomy\", section on 'Follow-up'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Among postmenopausal women, perioperative estrogen therapy (ET) may promote vaginal wound healing after gynecologic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, further study is needed to confirm the safety and efficacy of this use of ET. In the only randomized trial to address this use of ET, 315 postmenopausal women undergoing vaginal hysterectomy for benign indications were randomized to transdermal ET for 14 days before and after surgery or vaginal ET for 14 days before surgery and no postoperative ET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/20\">",
"     20",
"    </a>",
"    ]. At four weeks after surgery, women in the transdermal ET group had a significantly decreased incidence of incomplete re-epithelialization of vaginal suture sites (5 versus 17 percent) and visible wound opening (0 versus 2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms associated with vaginal dehiscence are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,4,6,8,14,22,23\">",
"     1,2,4,6,8,14,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic pain &mdash; 60 to 100 percent",
"     </li>",
"     <li>",
"      Vaginal bleeding &mdash; 30 to 60 percent",
"     </li>",
"     <li>",
"      Vaginal discharge or gush of fluid &mdash; 30 percent",
"     </li>",
"     <li>",
"      Vaginal pressure or mass &mdash; 30 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women have presented with cuff dehiscence up to five years postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the largest review (59 cases of dehiscence), the time interval from surgery to dehiscence ranged from 6 to 20 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For premenopausal women, dehiscence occurs early in the postoperative course (two to five months) and the most common trigger is first postoperative coitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,8,11,14,22,23\">",
"     1,2,8,11,14,22,23",
"    </a>",
"    ]. In contrast, in postmenopausal women, vaginal cuff rupture is commonly associated with pelvic organ prolapse and may occur months to years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/2,4,8,9,24\">",
"     2,4,8,9,24",
"    </a>",
"    ]. One hypothesis is that later rupture results from progressive weakening of the vaginal scar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may present with partial or complete dehiscence of the vaginal cuff. The larger the vaginal cuff dehiscence, the greater the risk of evisceration of an organ through the vaginal cuff defect. Bowel is the organ that is most likely to present through the separated vaginal cuff; the distal ileum is the most common bowel segment. Other reported structures include: omentum, fallopian tube, appendix, and bowel epiploica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,2,4,8,11,14,22,25\">",
"     1,2,4,8,11,14,22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bowel evisceration may lead to bowel injury, including perforation or incarceration with subsequent strangulation, necrosis, peritonitis, or sepsis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal cuff dehiscence with or without evisceration is a clinical diagnosis.",
"   </p>",
"   <p>",
"    A pelvic examination is essential for diagnosis. The vaginal cuff defect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eviscerating structure may be visualized on speculum examination or palpated on bimanual pelvic examination. The presence of pelvic floor defects should be noted and the vaginal cuff inspected for hematoma, cellulitis, or abscess.",
"   </p>",
"   <p>",
"    The site of vaginal cuff dehiscence after hysterectomy is typically the vaginal incision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An abdominal examination should be performed to evaluate for peritonitis or signs of bowel obstruction.",
"   </p>",
"   <p>",
"    Stable patients without bowel evisceration may be candidates for transvaginal repair without abdominal exploration. If there is any clinical concern, the abdomen and pelvis should be imaged (eg, computed tomography or magnetic resonance imaging) to evaluate the bowel and identify predisposing factors for dehiscence, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaginal cuff hematoma or abscess",
"     </li>",
"     <li>",
"      Bowel obstruction or perforation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal or pelvic mass, malignancy, or foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, if the vaginal cuff is repaired laparoscopically, then the abdomen and pelvis can be directly explored during surgery and preoperative imaging may not be necessary. If bowel evisceration is present, the patient is best assessed in the operating room. Since bowel evisceration can lead to peritonitis and sepsis, all vaginal eviscerations should be considered a surgical emergency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal cuff dehiscences can present as complete or partial separation of the vaginal incision with or without bowel evisceration. All dehiscences with evisceration should be repaired surgically. Place intravenous lines for fluid and medication management.",
"   </p>",
"   <p>",
"    For cuff dehiscences without evisceration, surgical management or expectant management may be employed. Some clinicians manage small dehiscences (ie, less than 25 percent separation) expectantly. In our practice, we prefer to close all recognized dehiscences since a partial separation may reflect the potential for further separation. Since there is no existing standard of care, each patient should be assessed individually.",
"   </p>",
"   <p>",
"    Of note, it is important to differentiate a vaginal cuff dehiscence (separation of the vaginal incision that was previously closed) from a gap on the vaginal cuff, where the latter reflects an opening on the vaginal incision due to a gap in suture placement. A gap on the vaginal cuff closure may be managed expectantly unless it is sufficiently large to pose evisceration risks. &nbsp;",
"   </p>",
"   <p>",
"    Vaginal cuff dehiscence exposes the peritoneal cavity to contamination from vaginal bacteria, and patients with evisceration, in particular, are at risk of peritonitis and sepsis. We give all patients with or without evisceration broad-spectrum antibiotics for 24 hours (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ). If an infection or bowel injury is present, the choice of antibiotics and length of treatment should be individualized.",
"   </p>",
"   <p>",
"    As soon as evisceration is recognized, the visible bowel should be inspected for injury. The prolapsed bowel or other structures should then be gently reduced. If the evisceration is successfully reduced, the vagina should be packed to minimize the risk of re-evisceration while preparing the patient for the operating room. A bladder catheter is placed prior to vaginal packing since the packing material may obstruct the bladder outlet. If the bowel is not reducible, the prolapsed structures should be irrigated with warm normal saline and wrapped in a moist towel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Choosing a surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the best mode of surgery for repair of the vaginal cuff dehiscence depends upon the patient's condition and the surgeon's experience. Various surgical approaches (vaginal, laparoscopic, abdominal, or a combination) have been described in the literature, but no standard exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1,4,22\">",
"     1,4,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to consider for surgical planning include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic status",
"     </li>",
"     <li>",
"      Bowel evisceration and the condition of the bowel contents (ie, viability, reducibility)",
"     </li>",
"     <li>",
"      Suspicion of other injuries (eg, bladder injury)",
"     </li>",
"     <li>",
"      Presence of pelvic floor defects that require concomitant surgical repair",
"     </li>",
"     <li>",
"      Vaginal cuff abscess or hematoma that may require drainage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      irrigation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bowel has eviscerated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraabdominal visceral injury is suspected, abdominal exploration at time of vaginal cuff repair is prudent. Abdominal exploration may be performed laparoscopically or via laparotomy. Vaginal cuff dehiscences without evisceration may be repaired vaginally without an abdominal survey. In fact, the majority of dehiscences are successfully repaired this way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there was no evisceration or if the eviscerating structure was reduced, copiously irrigate the vaginal dehiscence site. Excise any areas of necrotic tissue on the cuff with a scalpel to expose viable tissue edges.",
"   </p>",
"   <p>",
"    If a hematoma is present, inspect it to confirm that it is not expanding and assess whether it should be drained and excised versus managed expectantly. Similarly, if there is a vaginal cuff abscess, it should be drained. For either condition, a drain may be indicated.",
"   </p>",
"   <p>",
"    To close the vaginal cuff, we use a delayed absorbable monofilament suture. Close the cuff as described above, taking care to avoid inadvertent injury to the bladder, rectum, or uterine vessels. If a bladder or bowel injury is noted, or adhesions to the cuff are suspected, cystoscopy, laparoscopy, or laparotomy may be needed for diagnosis and therapy (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgical technique'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postoperative care and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise patients to delay resumption of vaginal intercourse for three months after vaginal dehiscence repair. As discussed above, estrogen replacement may potentiate vaginal wound healing in postmenopausal women.",
"   </p>",
"   <p>",
"    Any underlying conditions that chronically increase abdominal pressures (eg, chronic cough, asthma, reflux) should be treated aggressively to minimize recurrent stress on the healing vaginal cuff (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Postoperative period'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    We see patients at 2, 6 and 12 weeks postoperatively after dehiscence repair and perform a vaginal speculum exam to confirm cuff closure and absence of infection or hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal cuff dehiscence is the separation of the vaginal incision after total hysterectomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal cuff dehiscence is rare. Major risk factors are: total laparoscopic hysterectomy, vaginal cuff infection, vaginal trauma (eg, coitus), and cigarette smoking. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic pain and vaginal bleeding are the most common clinical symptoms. Evisceration of the bowel or other structures is a less common, but much more serious sequelae of dehiscence. Bowel evisceration can lead to bowel necrosis and subsequent peritonitis and sepsis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal cuff dehiscence is diagnosed by physical examination. Evisceration and hemodynamic instability should be addressed promptly. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repair of a dehiscence without evisceration can be performed using a vaginal or abdominal approach; however, injury or incarceration of bowel requires abdominal exploration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Choosing a surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive strategies include: optimizing vaginal cuff tissue quality and security of closure, and avoidance of vaginal intercourse or other vaginal insertions for at least four weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing total laparoscopic hysterectomy, in whom the colpotomy is made with a device that uses an energy source (eg, electrosurgery, ultrasonic energy), we suggest use of techniques that minimize tissue necrosis rather than other techniques (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Colpotomy with a sharp instrument is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/1\">",
"      Hur HC, Guido RS, Mansuria SM, et al. Incidence and patient characteristics of vaginal cuff dehiscence after different modes of hysterectomies. J Minim Invasive Gynecol 2007; 14:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/2\">",
"      Iaco PD, Ceccaroni M, Alboni C, et al. Transvaginal evisceration after hysterectomy: is vaginal cuff closure associated with a reduced risk? Eur J Obstet Gynecol Reprod Biol 2006; 125:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/3\">",
"      Donellan, NM, Hur, HC, Mansuria, NM, et al. Incidence of vaginal cuff dehiscence after different modes of hysterectomy. publication pending 2010; .",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/4\">",
"      Croak AJ, Gebhart JB, Klingele CJ, et al. Characteristics of patients with vaginal rupture and evisceration. Obstet Gynecol 2004; 103:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/5\">",
"      Robinson BL, Liao JB, Adams SF, Randall TC. Vaginal cuff dehiscence after robotic total laparoscopic hysterectomy. Obstet Gynecol 2009; 114:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/6\">",
"      Agdi M, Al-Ghafri W, Antolin R, et al. Vaginal vault dehiscence after hysterectomy. J Minim Invasive Gynecol 2009; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/7\">",
"      Uccella S, Ghezzi F, Mariani A, et al. Vaginal cuff closure after minimally invasive hysterectomy: our experience and systematic review of the literature. Am J Obstet Gynecol 2011; 205:119.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/8\">",
"      Ramirez PT, Klemer DP. Vaginal evisceration after hysterectomy: a literature review. Obstet Gynecol Surv 2002; 57:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/9\">",
"      Kowalski LD, Seski JC, Timmins PF, et al. Vaginal evisceration: presentation and management in postmenopausal women. J Am Coll Surg 1996; 183:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/10\">",
"      Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol 1990; 163:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/11\">",
"      Cardosi RJ, Hoffman MS, Roberts WS, Spellacy WN. Vaginal evisceration after hysterectomy in premenopausal women. Obstet Gynecol 1999; 94:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/12\">",
"      Walsh CA, Sherwin JR, Slack M. Vaginal evisceration following total laparoscopic hysterectomy: case report and review of the literature. Aust N Z J Obstet Gynaecol 2007; 47:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/13\">",
"      Kho RM, Akl MN, Cornella JL, et al. Incidence and characteristics of patients with vaginal cuff dehiscence after robotic procedures. Obstet Gynecol 2009; 114:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/14\">",
"      Y&uuml;ce K, Dursun P, G&uuml;ltekin M. Posthysterectomy intestinal prolapse after coitus and vaginal repair. Arch Gynecol Obstet 2005; 272:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/15\">",
"      Purakal J, Moyer G, Burke W. Vaginal cuff dehiscence after hysterectomy in a woman with systemic lupus erythematosus: a case report. J Reprod Med 2008; 53:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/16\">",
"      Zambrano D. Clindamycin in the treatment of obstetric and gynecologic infections: a review. Clin Ther 1991; 13:58.",
"     </a>",
"    </li>",
"    <li>",
"     Shen, CC. Comparison of One- and Two-Layer Vaginal Cuff Closure and Open Vaginal Cuff during Laparoscopic-Assisted Vaginal Hysterectomy. J Am Assoc Gynecol Laparosc 9: 474.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/18\">",
"      Siedhoff MT, Yunker AC, Steege JF. Decreased incidence of vaginal cuff dehiscence after laparoscopic closure with bidirectional barbed suture. J Minim Invasive Gynecol 2011; 18:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/19\">",
"      Kirsner RS, Eaglstein WH. The wound healing process. Dermatol Clin 1993; 11:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/20\">",
"      Vesna A, Neli B. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial). Maturitas 2006; 53:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/21\">",
"      Pushkar' DIu, D'iakov VV, Godunov BN, Gvozdev MIu. [Ovestin in preparation for transvaginal surgeries]. Urologiia 2002; :34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/22\">",
"      Nezhat CH, Nezhat F, Seidman DS, Nezhat C. Vaginal vault evisceration after total laparoscopic hysterectomy. Obstet Gynecol 1996; 87:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/23\">",
"      Joy SD, Phelan M, McNeill HW. Postcoital vaginal cuff rupture 10 months after a total vaginal hysterectomy. A case report. J Reprod Med 2002; 47:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/24\">",
"      Nasr AO, Tormey S, Aziz MA, Lane B. Vaginal herniation: case report and review of the literature. Am J Obstet Gynecol 2005; 193:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41990/abstract/25\">",
"      Kambouris AA, Drukker BH, Barron J. Vaginal evisceration. A case report and brief review of the literature. Arch Surg 1981; 116:949.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3271 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41990=[""].join("\n");
var outline_f41_0_41990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of laparoscopic hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8609085\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postoperative period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Choosing a surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postoperative care and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32490?source=related_link\">",
"      Abdominal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41991="Adjuvant treatment of high-risk endometrial cancers";
var content_f41_0_41991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant treatment of high-risk endometrial cancers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Gini Fleming, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Paul A DiSilvestro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41991/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/0/41991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H176023542\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinomas of the endometrium are the most common gynecologic malignancy in developed countries and the second most common in developing countries. Among the different histologic types of adenocarcinomas, endometrioid uterine cancers have a favorable prognosis and typically present at an early stage. Other histologic types of uterine adenocarcinoma (eg, serous, clear cell) are associated with a poorer prognosis.",
"   </p>",
"   <p>",
"    The American Joint Committee on Cancer (AJCC) and International Federation of Gynecology and Obstetrics (FIGO) combined staging system is used to designate cancer stage (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ). In addition to stage, other pathologic factors are used to assign risk for recurrent or persistent disease into low-, intermediate-, and high-risk.",
"   </p>",
"   <p>",
"    Women with high-risk endometrial cancer have a poor prognosis following surgery alone. Therefore, adjuvant treatment is often administered, although the effect of any therapy following surgery on overall survival is unclear. This review will focus on treatment of high-risk endometrial cancer.",
"   </p>",
"   <p>",
"    An overview of endometrial cancer, including clinical features and an approach to diagnosis, the approach to adjuvant treatment, and treatment of both low- and intermediate-risk endometrial cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link\">",
"       \"Overview of endometrial carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37992?source=see_link\">",
"       \"Endometrial carcinoma: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8855?source=see_link\">",
"       \"Approach to adjuvant treatment of endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13287?source=see_link\">",
"       \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7542?source=see_link\">",
"       \"Treatment of low-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22825?source=see_link\">",
"       \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125239170\">",
"    <span class=\"h1\">",
"     DEFINITION OF HIGH-RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are classified as having high-risk endometrial cancer if they have serous or clear cell adenocarcinoma (any stage) or pathologic stage III disease (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some experts also include the presence of specific risk factors for women with early stage endometrial cancer (ie, deep myometrial invasion, grade 3 disease, tumor lymphovascular space invasion [LVSI]) in this group because they confer an increased risk of both progression and death from disease. (See",
"    <a class=\"local\" href=\"#H391761112\">",
"     'High intermediate-risk disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13287?source=see_link\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence to support this definition of high-risk are reviewed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181148975\">",
"    <span class=\"h2\">",
"     Uterine serous or clear cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to endometrioid adenocarcinomas, uterine serous and clear cell carcinomas are more aggressive histologic types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. This was demonstrated in a Surveillance, Epidemiology and End Results (SEER) study of cases diagnosed from 1998 to 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. The five-year survival rate stratified by histologic type was 45, 65, and 91 percent for serous, clear cell, and endometrioid adenocarcinomas, respectively.",
"   </p>",
"   <p>",
"    This poorer prognosis was evidence when stratified by stage at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among women diagnosed with stage I serous, clear cell, or endometrioid cancers, the five-year survival rate was 74, 88, and 95 percent.",
"     </li>",
"     <li>",
"      Among women with stage II cancers, it was 56, 67, and 86 percent, respectively.",
"     </li>",
"     <li>",
"      Among women with stage III cancers, it was 33, 48, and 67 percent, respectively.",
"     </li>",
"     <li>",
"      Among women with stage IV cancers, it was 18, 18, and 37 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181148990\">",
"    <span class=\"h2\">",
"     Stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to women with early stage I or II endometrial cancer (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ), patients with surgical and pathologic stage III endometrial cancer have a lower five-year survival rate (60 versus 97 and 80 percent for stage I and II, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. However, outcomes appear to differ based on grade. Among women with stage III disease, those with grade 1 adenocarcinoma have a higher five-year survival rate (83 versus 68 and 48 percent for women with grade 2 or 3 tumors, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391761112\">",
"    <span class=\"h2\">",
"     High intermediate-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to histologic type and stage, individual experts and cooperative groups also include women with intermediate-risk",
"    <strong>",
"    </strong>",
"    endometrial",
"    <strong>",
"    </strong>",
"    cancer in clinical trials of high-risk endometrial cancer based on three tumor-associated risk factors: grade 2 or 3 endometrioid tumors, outer third myometrial invasion, or lymphovascular space invasion. The Gynecologic Oncology Group (GOG) uses these factors to identify the following women in clinical trials in high-risk endometrial cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients of any age with all three risk factors",
"     </li>",
"     <li>",
"      Patients 50 to 69 years old with two factors",
"     </li>",
"     <li>",
"      Patients who are 70 years or older with only one factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion on the approach to women with high intermediate-risk endometrial cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13287?source=see_link&amp;anchor=H1596988042#H1596988042\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\", section on 'High intermediate-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176023614\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of high quality data to help guide recommendations, there is no uniform approach to the treatment of women with high-risk endometrial cancer. For women with surgically and pathologically defined high-risk endometrial cancer, we take into account whether disease is confined to the uterus (stage",
"    <span class=\"nowrap\">",
"     I/II)",
"    </span>",
"    or whether disease extends outside of the uterus (stage III) (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women with bulky stage III disease not amenable to surgery cannot be cured by non-surgical therapy alone and these patients are treated similarly to women with recurrent or metastatic endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22825?source=see_link\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181149540\">",
"    <span class=\"h2\">",
"     Stage I or II serous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrence and death for women with stage I or II serous carcinoma is dependent on the extent of tumor involvement. Treatment options include radiation therapy (RT, either with vaginal brachytherapy or pelvic RT), adjuvant chemotherapy, or a combined approach (chemotherapy plus RT). Given the paucity of data to help inform treatment recommendations, women with stage I or II serous carcinoma should consider treatment in the setting of a clinical trial. (See",
"    <a class=\"local\" href=\"#H97091274\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our approach takes into account the histologic type and stage of disease at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110942168\">",
"    <span class=\"h3\">",
"     Stage IA disease without myometrial invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data are limited, women with endometrial serous carcinoma without myometrial invasion (subset of stage IA) are at a lower risk of recurrence compared to women with myometrial invasion (9 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, we prefer to treat these patients with vaginal brachytherapy alone rather than adjuvant chemotherapy (with or without RT). However, given the overall low risk of recurrence, observation may be a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110942175\">",
"    <span class=\"h3\">",
"     Stage IA or IB disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with early stage serous carcinoma with myometrial invasion (stage IA or IB), we suggest adjuvant chemotherapy plus RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. We prefer vaginal brachytherapy rather than pelvic RT based on the results of the Post-Operative RT in Endometrial Cancer 2 (PORTEC-2) trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13287?source=see_link&amp;anchor=H19343690#H19343690\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\", section on 'Vaginal brachytherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest dataset supporting this approach comes from the Uterine Papillary Serous Carcinoma Consortium study that included 142 women with stage I serous cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/3\">",
"     3",
"    </a>",
"    ]. Following surgery, 23 percent received no further treatment while 14 and 63 percent were treated with adjuvant RT alone or adjuvant chemotherapy, respectively. Of those receiving chemotherapy (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ), 37 percent also received RT. Adjuvant chemotherapy was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically significant reduction in the recurrence rate (11 versus 30 and 25 percent with surgery alone or surgery followed by RT, respectively).",
"     </li>",
"     <li>",
"      A statistically significant improvement in five-year progression-free survival (PFS, 82, 64, and 65 percent, respectively).",
"     </li>",
"     <li>",
"      An improvement in five-year cancer specific survival (88, 60, and 70 percent, respectively) that was statistically nonsignificant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with most retrospective studies, there is the possibility of bias in the selection of treatments and particularly, in who did or did not receive chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110942183\">",
"    <span class=\"h3\">",
"     Stage II disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with stage II serous carcinoma, we suggest adjuvant chemotherapy plus vaginal brachytherapy.",
"   </p>",
"   <p>",
"    In the only report on outcomes for women with stage II serous carcinoma, 18 percent had no further treatment following surgery, 47 percent received adjuvant RT, and 25 percent received adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/7\">",
"     7",
"    </a>",
"    ]. RT was administered to 63 percent of those treated with chemotherapy. Adjuvant chemotherapy was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically significant reduction in the recurrence rate (10 versus 50 percent, respectively).",
"     </li>",
"     <li>",
"      A statistically significant improvement in PFS (88 versus 64 percent, respectively).",
"     </li>",
"     <li>",
"      An improvement in overall survival (OS, 86 versus 41 percent), although it was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181149547\">",
"    <span class=\"h2\">",
"     Stage I or II clear cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective data to help define the optimal management of women with disease confined to the uterus. We suggest vaginal brachytherapy (with or without pelvic radiation therapy) to reduce the risk of locoregional recurrence. The limited data suggest that chemotherapy plays little (if any) role in the adjuvant treatment of these patients. Thus, we suggest not administering chemotherapy concomitantly with RT.",
"   </p>",
"   <p>",
"    This recommendation is supported by an observational study of 80 patients treated at a single institution, 66 percent of whom had stage I or II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/8\">",
"     8",
"    </a>",
"    ]. Adjuvant treatment consisted of RT alone (22 percent), chemotherapy plus vaginal brachytherapy (51 percent) or chemotherapy alone (15 percent). For patients with early stage (I and II) clear cell cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal brachytherapy was associated with a statistically significant improvement in OS (median, 140 versus 50 months if no RT was given) but not in PFS.",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy administered alone or concomitantly with vaginal brachytherapy was not associated with an improvement in PFS or OS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of high quality data, we suggest not administering adjuvant chemotherapy. However, some experts would recommend adjuvant chemotherapy given the high risk of recurrence with clear cell carcinomas. In the absence of data, we feel this is a reasonable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181148949\">",
"    <span class=\"h2\">",
"     Stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with extrauterine disease (stage III), we recommend chemotherapy rather than RT. Adjuvant chemotherapy is associated with improvement in both progression-free and overall survival, regardless of whether RT is used. However, women with stage IIIA grade 1 endometrioid cancers appear to have a better prognosis compared to women with grade 2 or 3 cancers (see",
"    <a class=\"local\" href=\"#H181148990\">",
"     'Stage III disease'",
"    </a>",
"    above). As such, some providers may prefer adjuvant RT rather than chemotherapy in this subset of women with stage III disease.",
"   </p>",
"   <p>",
"    The benefit of adjuvant chemotherapy for women with stage III endometrial cancer was demonstrated in a 2011 meta-analysis of nine randomized trials that directly compared no further treatment following surgery with adjuvant platinum-based chemotherapy alone or adjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/9\">",
"     9",
"    </a>",
"    ]. The use of platinum-based combination chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduced risk of mortality (hazard ratio [HR] for mortality 0.74, 95% CI 0.62-0.89)",
"     </li>",
"     <li>",
"      An reduced risk of disease-progression (HR for progression 0.75, 95% CI 0.62-0.89)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of adjuvant chemotherapy was demonstrated best in Gynecologic Oncology Group Trial 122 (GOG 122), which was the only trial to specifically enroll a high-risk population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/10\">",
"     10",
"    </a>",
"    ]. In this trial, 388 women with stage III or IV endometrial cancer (residual disease limited to &lt;2 cm) were randomly assigned treatment with whole abdominal radiation therapy (WART, delivered as 30 Gy in 20 fractions) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    every three weeks for up to seven courses. Adjuvant doxorubicin plus cisplatin resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in progression-free survival (PFS) compared to WART (hazard ratio [HR] 0.71, 95% CI, 0.55-0.91). This translated into an improvement in PFS at five years (42 versus 38 percent, respectively).",
"     </li>",
"     <li>",
"      An improvement in overall survival (OS) (HR 0.68, 95% CI, 0.52-0.89). This translated into an improvement in OS at five years (53 versus 42 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these advantages,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was also associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher pelvic recurrence rate (18 versus 13 percent with WART).",
"     </li>",
"     <li>",
"      An increased incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic events including neutropenia (85 versus &lt;1 percent) and thrombocytopenia (21 versus 3 percent). This translated into a higher proportion of patients experiencing at least one grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      hematologic toxicity of any type (88 versus 14 percent). However, the study was conducted before the era of routine use of G-CSF, which would have ameliorated the neutropenic toxicity seen with chemotherapy.",
"     </li>",
"     <li>",
"      An increased incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      non-hematologic toxicity, including gastrointestinal adverse events (20 versus 13 percent) and neurologic toxicities (15 versus 7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1246851565\">",
"    <span class=\"h3\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several platinum-based combination chemotherapy regimens have been evaluated in clinical trials, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (AP), and AP plus paclitaxel (TAP).",
"   </p>",
"   <p>",
"    For most women with high-risk endometrial cancer, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in the adjuvant setting. However, AP is a reasonable alternative based on the results of GOG 122 (see",
"    <a class=\"local\" href=\"#H181148949\">",
"     'Stage III disease'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Our preference for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in the adjuvant setting is based on the results of GOG 209, which were presented at the 2012 Society of Gynecologic Oncology Annual Meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/11\">",
"     11",
"    </a>",
"    ]. This trial compared carboplatin plus paclitaxel to TAP in 1300 women with chemotherapy na&iuml;ve advanced endometrial cancer, including women with stage III disease, and demonstrated that carboplatin and paclitaxel results in an equivalent overall response rate, similar progression-free survival, but is also less toxic. The results of GOG 209 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22825?source=see_link&amp;anchor=H99029909#H99029909\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\", section on 'Cisplatin, doxorubicin, plus paclitaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest not administering TAP as an adjuvant treatment because there is no improvement in survival outcomes compared to AP to justify the additional toxicity risks. This was demonstrated in GOG 184, in which 552 women with advanced endometrial cancer underwent volume-directed RT and then were randomly assigned treatment with AP or TAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/12\">",
"     12",
"    </a>",
"    ]. TAP did not improve the risk of recurrence compared to AP, nor did it improve recurrence free survival. However, it was associated with a worse toxicity profile. The overall survival results have not been presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181149306\">",
"    <span class=\"h3\">",
"     Is there a role for chemotherapy plus radiation?",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with stage III endometrial cancer, we recommend chemotherapy as a single modality treatment because the risk for distant metastases is as high as the risk for a local recurrence. In addition, RT is associated with an increased risk of both acute (eg, myelosuppression) and late toxicities (eg, radiation enteritis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22570?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Treatment-related toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some experts prefer to combine chemotherapy plus tumor-directed RT in order to reduce the risk of both local and distant recurrence, particularly in patients with a good performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ). Multiple single-arm clinical trials have demonstrated the feasibility of combined modality treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/13-16\">",
"     13-16",
"    </a>",
"    ], but there are only limited data from retrospective studies that show combined modality treatment improves outcomes compared to chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We encourage participation in well designed clinical trials, such as the",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00942357\">",
"     GOG 258 trial",
"    </a>",
"    that evaluates the use of chemotherapy alone (six cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) versus volume-directed RT with concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed chemotherapy (four cycles of carboplatin plus paclitaxel). (See",
"    <a class=\"local\" href=\"#H97091274\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97091201\">",
"    <span class=\"h2\">",
"     Is there a role for adjuvant endocrine therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with high-risk endometrial adenocarcinoma, we recommend not using endocrine therapy as adjuvant treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7542?source=see_link&amp;anchor=H189467855#H189467855\">",
"     \"Treatment of low-risk endometrial cancer\", section on 'Progestin therapy'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97091274\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, we agree with the National Comprehensive Cancer Network and prefer that women with high-risk endometrial cancer participate in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/18\">",
"     18",
"    </a>",
"    ]. Clinical trials available for women with high-risk endometrial cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00411138\">",
"       PORTEC 3",
"      </a>",
"      &mdash; The Postoperative Radiation Therapy for Endometrial Cancer 3 (PORTEC-3) trial is open to women with high-risk stage I (including women with serous or clear cell cancers), stage II and III endometrial cancer who are randomly assigned to treatment with adjuvant pelvic radiation therapy (RT) alone or to RT with concomitant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      followed by four cycles of chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00942357\">",
"       GOG 258",
"      </a>",
"      &mdash; The Gynecologic Oncology Group 258 trial (GOG 258) is open to women with stage I or II serous or clear cell cancer with positive peritoneal cytology or women with optimally resected (ie, residual tumor after surgery at any one site &le;2 cm) stage III or IVA endometrial cancer. Patients are randomly assigned to adjuvant chemotherapy alone (six cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ) or to concomitant chemoradiation followed by four cycles of adjuvant carboplatin plus paclitaxel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25537000\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118964896\">",
"    <span class=\"h2\">",
"     Newly diagnosed stage IV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with metastatic endometrial cancer extending to the bladder or rectum (stage IVA) or to the abdominal cavity or other visceral organs (ie, liver or lung, stage IVB), the five-year overall survival rate is approximately 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. Women with disease limited to the pelvis or abdominal carcinomatosis may be candidates for surgical cytoreduction based on retrospective series showing superior outcomes with optimal surgical debulking, regardless of histologic subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link&amp;anchor=H14#H14\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, upfront surgery may be challenging, particularly in women with bulky upper abdominal disease, and there is no high quality evidence that adjuvant chemotherapy following surgery improves outcomes for women with metastatic endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22825?source=see_link\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82069962\">",
"    <span class=\"h2\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age has been associated with higher rates of clinical failure, but whether age represents an independent prognostic factor is controversial. Women over the age of 65 more frequently have deep myometrial invasion, high tumor grade, and advanced tumor stage. Furthermore, less aggressive therapy could also account for some of the poor outcomes seen in older patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8855?source=see_link&amp;anchor=H215731105#H215731105\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Influence of age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because organ function declines and the number of comorbidities increases as women become older, the risks of chemotherapy are potentially magnified. As such, it becomes less clear if women will live long enough to experience potential survival benefits of treatment to justify the expected risks of chemotherapy. Therefore, we suggest older women undergo comprehensive geriatric assessment to aid in decisions regarding adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189460926\">",
"    <span class=\"h2\">",
"     Obese women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial cancer is associated with obesity, and morbid obesity is common among endometrial cancer patients. Although clinical practice varies, overweight or obese women often receive intentionally reduced chemotherapy doses based upon ideal rather than actual body weight. However, there are no data to support this practice. We agree with guidelines from the American Society of Clinical Oncology and suggest full weight-based cytotoxic chemotherapy dosing in the adjuvant setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189464454\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with high-risk endometrial cancer are at an increased risk of disease progression and death from their disease, even when detected at an early stage. Beyond histologic subtype, prognosis is highly dependent on both stage and tumor grade. For example, in a Surveillance, Epidemiology and End Results (SEER) study of over 44,000 women, five-year survival was 97, 80, 60 and 25 percent for stage I, II, III or IV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. Among women with stage III disease, five-year relative survival is 83, 68, and 48 percent for grade 1, 2, or 3 adenocarcinomas, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41991/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link&amp;anchor=H4679282#H4679282\">",
"     \"Overview of endometrial carcinoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176024414\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of recurrences occur within three years of treatment. Approximately 70 percent of patients develop symptoms at the time of recurrence (eg, vaginal bleeding, abdominal pain, cough, weight loss). While posttreatment surveillance protocols may vary by institution, we suggest clinical exam (including symptom review, symptom-directed physical exam, and pelvic exam) at three month intervals for two years, then six months or annually. While CA-125 is used by some clinicians as part of routine surveillance, there is no high quality evidence that CA-125 surveillance improves outcomes. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176024114\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with uterine serous carcinoma or clear cell carcinoma confined to the uterus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cervical stroma or optimally resected stage III disease of any histology are at high risk of recurrence and death from their cancer. (See",
"      <a class=\"local\" href=\"#H176023542\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are classified as having high-risk endometrial cancer if they have serous or clear cell adenocarcinoma (any stage) or pathologic stage III disease (",
"      <a class=\"graphic graphic_table graphicRef51307 \" href=\"mobipreview.htm?42/33/43549\">",
"       table 1",
"      </a>",
"      ). Some experts also include the presence of specific risk factors for women with early stage endometrial cancer (ie, deep myometrial invasion, grade 3 disease, tumor lymphovascular space invasion [LVSI]) in this group. (See",
"      <a class=\"local\" href=\"#H125239170\">",
"       'Definition of high-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage IA serous carcinoma without myometrial invasion, we suggest adjuvant vaginal brachytherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, given the overall low risk of recurrence, observation may be a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H2110942168\">",
"       'Stage IA disease without myometrial invasion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage IA (with myometrial invasion), IB, and II serous carcinoma, we suggest adjuvant chemotherapy plus vaginal brachytherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      rather than other platinum-based combination regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2110942175\">",
"       'Stage IA or IB disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2110942183\">",
"       'Stage II disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1246851565\">",
"       'Choice of chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      clear cell cancer, we suggest adjuvant radiation therapy alone rather than chemotherapy plus radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some clinicians prefer to administer adjuvant chemotherapy, and in the absence of high quality data, this is a reasonable option. (See",
"      <a class=\"local\" href=\"#H181149547\">",
"       'Stage I or II clear cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage III endometrial cancer, we recommend adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      rather than other combinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These women are at high risk for distant metastases. Some experts prefer to combine chemotherapy plus tumor-directed radiation therapy in order to reduce the risk of both local and distant recurrence, particularly in patients with a good performance status. In the absence of high quality data, this is a reasonable alternative treatment option. (See",
"      <a class=\"local\" href=\"#H181148949\">",
"       'Stage III disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kosary C. Cancer of the Corpus Uteri. In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. NCI, SEER Program, National Cancer Institute; Bethesda, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/2\">",
"      Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007; 105:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/3\">",
"      Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009; 115:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/4\">",
"      Kelly MG, O'malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/5\">",
"      Elit L, Kwon J, Bentley J, et al. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 2004; 92:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/6\">",
"      Huh WK, Powell M, Leath CA 3rd, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003; 91:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/7\">",
"      Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 2009; 112:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/8\">",
"      Varughese J, Hui P, Lu L, et al. Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. J Oncol 2011; 2011:628084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/9\">",
"      Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011; :CD003175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/10\">",
"      Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24:36.",
"     </a>",
"    </li>",
"    <li>",
"     Miller DS, Filiaci G, Mannel R, et al. Randomized Phase III Noninferiority Trial of First Line Chemotherapy for Metastatic or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. LBA2. Presented at the 2012 Society of Gynecologic Oncology Annual Meeting, Austin, TX.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/12\">",
"      Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 112:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/13\">",
"      Einstein MH, Frimer M, Kuo DY, et al. Phase II trial of adjuvant pelvic radiation \"sandwiched\" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol 2012; 124:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/14\">",
"      Bruzzone M, Miglietta L, Franzone P, et al. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 2004; 93:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/15\">",
"      Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/16\">",
"      Mangili G, De Marzi P, Beatrice S, et al. Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer 2006; 6:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/17\">",
"      Secord AA, Geller MA, Broadwater G, et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 2013; 128:65.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology- Uterine Neoplasms (Version 2.2012) file://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (Accessed on March 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/19\">",
"      Patsavas K, Woessner J, Gielda B, et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol 2011; 121:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/20\">",
"      Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol 2010; 119:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/21\">",
"      Shih KK, Yun E, Gardner GJ, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 2011; 122:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/22\">",
"      Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41991/abstract/23\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16721 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41991=[""].join("\n");
var outline_f41_0_41991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H176024114\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176023542\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H125239170\">",
"      DEFINITION OF HIGH-RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181148975\">",
"      Uterine serous or clear cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181148990\">",
"      Stage III disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H391761112\">",
"      High intermediate-risk disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176023614\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181149540\">",
"      Stage I or II serous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110942168\">",
"      - Stage IA disease without myometrial invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110942175\">",
"      - Stage IA or IB disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110942183\">",
"      - Stage II disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181149547\">",
"      Stage I or II clear cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181148949\">",
"      Stage III disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1246851565\">",
"      - Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181149306\">",
"      - Is there a role for chemotherapy plus radiation?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97091201\">",
"      Is there a role for adjuvant endocrine therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97091274\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25537000\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118964896\">",
"      Newly diagnosed stage IV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H82069962\">",
"      Older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189460926\">",
"      Obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189464454\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176024414\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176024114\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/33/43549\" title=\"table 1\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22825?source=related_link\">",
"      Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7542?source=related_link\">",
"      Treatment of low-risk endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41992="Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer";
var content_f41_0_41992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41992/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/0/41992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, bladder cancer accounts for almost 390,000 cases and 150,000 deaths. In developed areas of the world, such as North America and Western Europe, these bladder cancers are predominantly urothelial. Despite radical cystectomy, approximately one-half of patients with deep, muscle-invasive bladder cancer involving the muscularis propria (T2), perivesical tissue (T3), or pelvic structures (T4) develop metastatic disease within two years and will usually succumb to their disease (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contemporary management of patients with muscle-invasive bladder cancer consists of a multimodal treatment approach comprised of surgery, neoadjuvant chemotherapy, and for select patients, neoadjuvant chemoradiation with the objective towards bladder preservation. However, despite the evidence that neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy improves survival for these patients compared to locoregional treatment alone, less than 20 percent of patients undergoing radical cystectomy actually receive neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will focus on the multimodal treatment of muscle-invasive urothelial bladder cancer. The surgical treatment of bladder cancer, the treatment of non-muscle invasive bladder cancer, the role of adjuvant chemotherapy in patients with bladder cancer, and the approach to metastatic bladder cancer is detailed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link\">",
"     \"Treatment of non-muscle-invasive bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210939004\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical cystectomy and bilateral pelvic lymphadenectomy remains the standard of care for patients with muscle-invasive bladder cancer. However, the high relapse rates following cystectomy alone for patients with muscle invasive bladder cancer has led to the use of neoadjuvant treatment. The appropriate treatment plan is dependent on whether patients are candidates for a bladder sparing approach: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with",
"      <strong>",
"       clinical stage T2-4a bladder cancer",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      ) who will undergo a radical cystectomy, we recommend neoadjuvant chemotherapy rather than neoadjuvant radiation therapy or primary surgery alone. The use of neoadjuvant chemotherapy has been shown to improve survival in this population. (See",
"      <a class=\"local\" href=\"#H210940763\">",
"       'Patients undergoing radical cystectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For select patients with",
"      <strong>",
"       clinical stage T2 bladder cancer who desire bladder preservation",
"      </strong>",
"      , we recommend combination chemotherapy plus radiation therapy (RT) rather than chemotherapy or RT as a single modality treatment. However, it is critical that appropriately selected patients be offered this approach. (See",
"      <a class=\"local\" href=\"#H210940253\">",
"       'Patients desiring bladder preservation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients must be clinically staged prior to initiation of treatment for bladder cancer. We typically perform computed tomography (CT) of the chest, abdomen and pelvis, and cystoscopy with transurethral resection of bladder tumor (TURBT). The diagnosis and staging of urothelial carcinoma is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210940763\">",
"    <span class=\"h1\">",
"     PATIENTS UNDERGOING RADICAL CYSTECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing a radical cystectomy, we recommend neoadjuvant chemotherapy. We recommend not administering RT as a single modality treatment.",
"   </p>",
"   <p>",
"    The administration of combination",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy has consistently demonstrated a survival benefit when given prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This was demonstrated in a 2003 meta-analysis of 11 randomized trials of cisplatin-based neoadjuvant chemotherapy plus local therapy versus local therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/7\">",
"     7",
"    </a>",
"    ]. Compared to local therapy alone, neoadjuvant cisplatin-based combination chemotherapy resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in overall survival (OS, hazard ratio [HR] for mortality 0.87, 95% CI 0.78-0.98). This translated into an absolute survival benefit of 5 percent.",
"     </li>",
"     <li>",
"      A lower risk of recurrence (HR for recurrence 0.81, 95% CI 0.74-0.90). This translated into an absolute disease-free survival benefit of 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210939438\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing neoadjuvant chemotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination regimens should be used. However, the ideal neoadjuvant chemotherapy regimen is not known. Commonly employed regimens administered in the neoadjuvant setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       MVAC &mdash;",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 15, and 22),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 2, 15, and 22),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2) administered every 28 days for three cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H971959904\">",
"       'MVAC'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       CMV &mdash;",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on days 1 and 8 plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2), with folinic acid (15 mg every six hours for four doses) on days 2 and 9, repeated every 28 days for three cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H971959911\">",
"       'CMV'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       GC &mdash;",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, 15) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2) every 28 days for a maximum of six cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H971959918\">",
"       'GC'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of a definitive standard of care, we prefer MVAC particularly for healthy patients less than 70 years of age. In older patients or those unable to tolerate this combination due to medical comorbidities, CMV and GC are reasonable alternatives.",
"   </p>",
"   <p>",
"    The data to support the use of these regimens is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971959904\">",
"    <span class=\"h3\">",
"     MVAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit and toxicity of MVAC was demonstrated in the INT-0080 trial, which enrolled 307 patients with T2-4a bladder cancer and randomly assigned treatment to neoadjuvant MVAC prior to surgery or surgery alone. Compared to surgery alone, neoadjuvant MVAC resulted in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically significant increase in the pathologic complete response (pCR) rate (38 versus 15 percent)",
"     </li>",
"     <li>",
"      An improvement in the five-year survival rate (57 versus 43 percent) and an increase in overall survival (OS) (median, 77 versus 46 months), which was not statistically significant",
"     </li>",
"     <li>",
"      A high rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic or gastrointestinal toxicity including neutropenia (57 percent), stomatitis (10 percent), nausea and vomiting (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971959911\">",
"    <span class=\"h3\">",
"     CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV was evaluated in a phase III study involving 976 patients with high-grade T2-T4aN0-NXM0 bladder cancer who were randomly assigned to three cycles of neoadjuvant CMV or no chemotherapy. All patients were then managed according to each institution's choice (ie, radical cystectomy or radiation therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/10\">",
"     10",
"    </a>",
"    ]. Neoadjuvant treatment with CMV resulted in a pCR rate of 33 percent. With a median follow-up of eight years, neoadjuvant CMV was associated with a reduction in the risk of death compared to local treatment alone (HR 0.84, 95% CI 0.72-0.99) [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/neoadjuvant-chemotherapy-for-urothelial-transitional-cell-bladder-cancer/abstract/19\">",
"     19",
"    </a>",
"    ]. This corresponds to an absolute improvement in OS at 10 years of six percent (30 to 36 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H971959918\">",
"    <span class=\"h3\">",
"     GC",
"    </span>",
"    &nbsp;&mdash;&nbsp;GC and MVAC have only been compared in retrospective studies as neoadjuvant therapy, but these studies suggest it results in similar rates of pCR and survival outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Despite the lack of prospective data, GC is administered in this setting based on data from studies performed in patients with metastatic urothelial carcinoma, which show six cycles of GC result in a better toxicity profile compared to MVAC without a major difference in OS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=see_link&amp;anchor=H933456754#H933456754\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\", section on 'GC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These studies show that neoadjuvant chemotherapy improves survival outcomes for this population. Further studies are required to define the optimal regimen for patients undergoing neoadjuvant chemotherapy for muscle invasive bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1244259799\">",
"    <span class=\"h2\">",
"     Neoadjuvant radiation therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a single modality, preoperative radiation therapy (RT) can eradicate disease in a small proportion of patients undergoing cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, subsequent randomized trials demonstrated that while preoperative RT can improve local control, it has no impact on survival when compared to cystectomy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Therefore, it should not be used in patients prior to radical cystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H501917112\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the completion of neoadjuvant chemotherapy, patients should proceed with radical cystectomy regardless of the clinical response. Although neoadjuvant chemotherapy results in a high response, the risk that persistent disease is present can only be addressed at the time of cystectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Southwest Oncology Group trial (S0219), 77 patients with T2-T4a bladder cancer were treated with three cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (TCG), followed by restaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/23\">",
"     23",
"    </a>",
"    ]. Following TCG, 34 patients (46 percent) had a clinical complete response, ten of whom underwent an immediate cystectomy. Of these ten, six had persistent tumor in the cystectomy specimen.",
"   </p>",
"   <p>",
"    Although it might be possible to identify patients who may not require cystectomy at the end of neoadjuvant chemotherapy, the data to support a tailored post-neoadjuvant surgical approach are limited. In one study of 104 patients with T2-T4aNx urothelial cancer, all of whom received three courses of neoadjuvant MVAC, all patients underwent clinical restaging at the end of treatment and selective surgical treatment performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/24\">",
"     24",
"    </a>",
"    ]. The main results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of those who underwent TURBT only (n=49), 37 had a pCR. The five-year survival rate for the group was 67 percent.",
"     </li>",
"     <li>",
"      Of those who underwent partial cystectomy for a residual monofocal lesions postchemotherapy (n=13), five patients recurred (two with superficial and three with locally invasive disease). The five-year survival rate was 69 percent.",
"     </li>",
"     <li>",
"      Of those who underwent radical cystectomy for persistent disease at the end of neoadjuvant treatment (n=39), 14 developed metastatic disease. The five-year survival rate was 46 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these findings, we and others consider bladder preservation inferior to radical cystectomy when attempting to achieve cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210940253\">",
"    <span class=\"h1\">",
"     PATIENTS DESIRING BLADDER PRESERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder preservation therapy is an appropriate option for patients who are not surgical candidates for and those who are interested in alternatives to a radical cystectomy. However, careful selection of patients is required, and all patients require careful cystoscopic surveillance following treatment since up to 40 percent of patients with cT2-4 disease may still require a radical cystectomy either due to failure to achieve a complete response (CR) or for recurrence after an initial complete response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate candidates for an attempt at bladder preservation include those who fulfill the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Appropriate candidates for TURBT",
"      </strong>",
"      &mdash; Eligibility for a complete transurethral resection of bladder tumor (TURBT) is a necessary prerequisite for safe bladder preservation. In one study, the ability to perform a complete TURBT was the only independent prognostic factor for long-term survival and successful bladder preservation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Adequate renal function",
"      </strong>",
"      &mdash; Patients must have sufficient kidney function to tolerate platinum-based chemoradiation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urothelial carcinoma",
"      </strong>",
"      &mdash; Nonurothelial histologies (ie, adenocarcinoma, squamous cell carcinoma) are generally insensitive to chemotherapy. Therefore, these patients should not be considered for a neoadjuvant bladder-sparing approach.",
"     </li>",
"     <li>",
"      <strong>",
"       Early stage disease",
"      </strong>",
"      &mdash; Patients with early tumors (T0-T2) at presentation are appropriate candidates for a bladder sparing approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/16,25,28\">",
"       16,25,28",
"      </a>",
"      ]. As an example, in a study of 170 patients with T2-T4 bladder cancer treated with chemoradiation, patients with more advanced disease were more likely to have persistent disease after treatment (44, 69, and 80 percent with preoperative T2, T3, and T4 tumors, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H501917562\">",
"    <span class=\"h2\">",
"     Primary chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are candidates for bladder preservation, we recommend primary chemoradiation. Primary chemoradiation is associated with improved local control and higher rates of bladder conserving surgery when compared with radiation therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/17,28,29\">",
"     17,28,29",
"    </a>",
"    ]. However, it has not been directly compared with neoadjuvant chemotherapy.",
"   </p>",
"   <p>",
"    The benefit of chemoradiation was demonstrated in the Bladder Cancer 2001 (BC2001) phase III trial that enrolled 360 patients with muscle-invasive bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/29\">",
"     29",
"    </a>",
"    ]. Following cystoscopic resection of tumor and biopsy, patients were randomly assigned treatment with RT alone or RT plus chemotherapy. The chemotherapy regimen consisted of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (12",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on RT days 1 to 5 and days 16 to 20). With a median follow-up of 70 months, chemoradiation resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of two-year locoregional disease-free survival compared to radiation alone (67 versus 54 percent, respectively; HR 0.68, 95% CI 0.48-0.96)",
"     </li>",
"     <li>",
"      A trend towards an improvement in the five-year rate of OS (48 versus 35 percent, respectively; HR 0.82, 95% CI 0.63-1.09)",
"     </li>",
"     <li>",
"      A higher rate of serious (grade 3 to 5) gastrointestinal toxicity (10 versus 3 percent, respectively; odds ratio [OR] 3.84, 95% CI 0.97-15.2)",
"     </li>",
"     <li>",
"      A lower rate of cystectomy at two years (11 versus 17 percent), which was not statistically significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618709098\">",
"    <span class=\"h3\">",
"     Is there a role for additional chemotherapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for additional systemic chemotherapy in patients undergoing chemoradiation for bladder preservation is not clear. However, limited data suggest additional chemotherapy may not be needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/17,25-27,30-36\">",
"     17,25-27,30-36",
"    </a>",
"    ]. In either case, normal bladder function is maintained long-term in the majority of this highly selected group of patients.",
"   </p>",
"   <p>",
"    In one of the largest trials evaluating chemotherapy plus chemoradiation, 190 patients with muscle-invasive urothelial cancer (stage T2-4a) were treated with TURBT, two courses of CMV chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ), and chemoradiation (external beam RT 40 Gy plus single agent cisplatin) with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical complete response (CR) rate was 71 and 57 percent among patients with T2 and T3-T4a tumors, respectively.",
"     </li>",
"     <li>",
"      The five and ten year disease-specific survival rates were 63 and 59 percent, respectively. The five and ten year disease-specific survival rates with an intact bladder were 46 and 45 percent, respectively.",
"     </li>",
"     <li>",
"      60 percent who had a CR were free of disease at a median follow-up of seven years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15490168\">",
"    <span class=\"h2\">",
"     Follow-up after chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients do not typically undergo repeat assessment during primary chemoradiation. However, at some centers, a repeat cystoscopy is done during RT. If there is evidence of residual disease, a radical cystectomy is performed. If no residual disease is found, patients continue the planned course of radiation.",
"   </p>",
"   <p>",
"    Following completion of chemoradiation, patients should undergo evaluation for disease extent. This typically consists of a computed tomography of the abdomen and pelvis and cystoscopy with biopsy and cytology taken. No further treatment is needed if there is no evidence of disease (ie, a complete response by biopsy, cytology, and imaging). These patients should proceed with posttreatment surveillance (see",
"    <a class=\"local\" href=\"#H210941663\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below). However, if there is evidence of residual disease, we recommend a radical cystectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618709291\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite evidence of a survival advantage, not everyone undergoing a radical cystectomy is treated with neoadjuvant chemotherapy. Unfortunately, there is a paucity of data regarding the use of adjuvant chemotherapy. The issue of adjuvant chemotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210940629\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic complete response (pCR) is associated with improved disease-free and overall survival. As an example, in the Southwest Oncology Group trial of MVAC plus cystectomy versus cystectomy alone, the median survival of patients with a pCR was not reached among those treated with MVAC prior to cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/9\">",
"     9",
"    </a>",
"    ]. For those with residual disease, median survival was four years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link&amp;anchor=H27#H27\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\", section on 'Risk of recurrence'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210941663\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have completed treatment for muscle-invasive bladder cancer, follow-up is essential for detection of recurrence (in the case of partial cystectomy or bladder preservation) or second primary along the urogenital tract. We agree with the National Comprehensive Cancer network guidelines for surveillance, which are stratified by surgical approach to the primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       For patients treated with cystectomy",
"      </strong>",
"      : We perform laboratory evaluations every three to six months for the first two years and then as clinically indicated. These should include urine cytology, liver and renal function tests, and electrolytes. We typically perform a chest x-ray and computed tomography (CT) of the abdomen and pelvis every 6 to 12 months for the first two years and then as clinically indicated.",
"     </li>",
"     <li>",
"      <strong>",
"       For patients treated with bladder preservation (TURBT or partial cystectomy)",
"      </strong>",
"      : In addition to the above evaluations for patients treated with cystectomy, we perform serial cystoscopies with cytologic evaluation every three to six months for the first two years with intervals based on physician discretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop new symptoms (ie, bladder pain or hematuria), a repeat cystoscopy should be performed to evaluate for recurrence. If confirmed, either bladder sparing surgery or radical cystectomy may be required. The surgical approach will depend on the nature of the relapse and the physical condition of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     p53 status for risk-directed clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the tumor suppressor gene p53 have been evaluated as a way to select patients for treatment. However, we recommend against routine study of p53 expression prior to neoadjuvant therapy outside an investigational setting.",
"   </p>",
"   <p>",
"    The association between p53 mutations and a poor prognosis in bladder cancer has not been consistently demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/38-44\">",
"     38-44",
"    </a>",
"    ]. As an example, in one study involving 243 patients who underwent cystectomy for pTa to pT4B disease, compared to p53 wild-type, the presence of p53 altered immunoreactivity was associated with a significantly higher risk of both disease recurrence and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/38\">",
"     38",
"    </a>",
"    ]. Recurrence rates for tumors with and without detectable p53 immunoreactivity were 62 versus 7 percent for pT1 tumors, 56 versus 12 percent for pT2 tumors, and 80 versus 11 percent for pT3 tumors. One adjuvant trial attempted to select bladder cancer patients with tumor positive for mutant p53 and randomly assign treatment with observation or adjuvant MVAC chemotherapy. However, this trial was closed at interim analysis due to futility and is reported as a negative trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/44\">",
"     44",
"    </a>",
"    ]. This trial is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link&amp;anchor=H1072936968#H1072936968\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\", section on 'Contemporary trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not responsiveness to neoadjuvant chemotherapy may be predicted based upon an individual tumor's gene expression pattern is an intriguing area of great interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41992/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Such work is in its infancy, but holds promise for future individualization of therapy. At present, many of the published results are preliminary, based on small sample sizes, and it is not possible to make a definitive statement on the role of gene expression profiling in the molecular prognostication of invasive bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite radical cystectomy, approximately one-half of patients with deep, muscle-invasive bladder cancer involving the muscularis propria (T2), perivesical tissue (T3), or pelvic structures (T4, including prostatic stroma, seminal vesicles, uterus, vagina, pelvic side wall or abdominal wall) develop metastatic disease within two years and most will succumb to their disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radical cystectomy and bilateral pelvic lymphadenectomy remains the standard of care for patients with muscle-invasive bladder cancer. For patients with T2-4a bladder cancer for whom a radical cystectomy is planned, we recommend neoadjuvant chemotherapy over surgery alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H210940763\">",
"       'Patients undergoing radical cystectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our preferred neoadjuvant regimen is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (MVAC). (See",
"      <a class=\"local\" href=\"#H210939438\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the completion of neoadjuvant chemotherapy, we recommend that all patients proceed with radical cystectomy. Although it might be possible to identify patients who may not require cystectomy at the end of neoadjuvant chemotherapy, the data to support a tailored post-neoadjuvant surgical approach are limited. We and others consider bladder preservation inferior to radical cystectomy when attempting to achieve cure. (See",
"      <a class=\"local\" href=\"#H501917112\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder sparing therapy may be considered a reasonable alternative to radical surgery in patients who are deemed unfit for cystectomy as well as for those seeking an alternative to radical cystectomy, provided that careful cystoscopic surveillance is conducted. For patients who undergo neoadjuvant treatment with the objective of bladder preservation, we recommend chemoradiation over radiation therapy (RT) alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H210940253\">",
"       'Patients desiring bladder preservation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the completion of primary chemoradiation, all patients should undergo evaluation for disease extent. (See",
"      <a class=\"local\" href=\"#H15490168\">",
"       'Follow-up after chemoradiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have completed treatment for muscle-invasive bladder cancer, follow-up is essential for detection of recurrence (in the case of partial cystectomy or bladder preservation) or second primary along the urogenital tract. (See",
"      <a class=\"local\" href=\"#H210941663\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop new symptoms (ie, bladder pain or hematuria), a repeat cystoscopy should be performed to evaluate for recurrence. If confirmed, either bladder sparing surgery or radical cystectomy may be required. The surgical approach will depend on the nature of the relapse and the physical condition of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1837314600\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Drs. Dean Bajorin, Bernard Bochner, and Michael Zelefsky, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/1\">",
"      Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990; 322:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/2\">",
"      Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/3\">",
"      Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/4\">",
"      David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007; 178:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/5\">",
"      Miles BJ, Fairey AS, Eliasziw M, et al. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Can Urol Assoc J 2010; 4:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/6\">",
"      Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011; 117:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/7\">",
"      Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/8\">",
"      Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/9\">",
"      Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/10\">",
"      Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/11\">",
"      von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/12\">",
"      Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/13\">",
"      Yeshchina O, Badalato GM, Wosnitzer MS, et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012; 79:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/14\">",
"      Whitmore WF Jr, Batata MA, Ghoneim MA, et al. Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 1977; 118:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/15\">",
"      Shipley WU, Cummings KB, Coombs LJ, et al. 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging. J Urol 1982; 127:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/16\">",
"      Schultz PK, Herr HW, Zhang ZF, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994; 12:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/17\">",
"      Shipley WU, Kaufman DS, Heney NM, et al. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999; 162:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/18\">",
"      Cole CJ, Pollack A, Zagars GK, et al. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/19\">",
"      Crawford ED, Das S, Smith JA Jr. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 1987; 14:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/20\">",
"      Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1977; 39:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/21\">",
"      Sell A, Jakobsen A, Nerstr&oslash;m B, et al. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991; 138:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/22\">",
"      Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982; 54:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/23\">",
"      deVere White RW, Lara PN Jr, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol 2009; 181:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/24\">",
"      Sternberg CN, Pansadoro V, Calabr&ograve; F, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/25\">",
"      Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993; 329:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/26\">",
"      Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/27\">",
"      R&ouml;del C, Grabenbauer GG, K&uuml;hn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/28\">",
"      Koga F, Fujii Y, Masuda H, et al. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches. BJU Int 2012; 110:E203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/29\">",
"      James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/30\">",
"      Given RW, Parsons JT, McCarley D, Wajsman Z. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995; 46:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/31\">",
"      Serretta V, Lo Greco G, Pavone C, Pavone-Macaluso M. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience. J Urol 1998; 159:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/32\">",
"      Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994; 30:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/33\">",
"      Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/34\">",
"      Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/35\">",
"      Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11:2150.",
"     </a>",
"    </li>",
"    <li>",
"     Efstathiou JA, Coen J, Spiegel DY, et al. 15-year outcomes of selective bladder preservation for invasive bladder cancer: The Massachusetts General Hospital experience (abstract). American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Sympsoium.",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (Version 2.2012) file://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (Accessed on May 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/38\">",
"      Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/39\">",
"      Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/40\">",
"      Garcia del Muro X, Munoz J, Condom E, et al. p21 and p53 as prognostic factors for bladder preservation and survival in patients with bladder cancer treated with neoadjuvant chemotherapy (abstract). Proc Am Soc Clin Oncol 2002; 21:179a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/41\">",
"      Herr HW, Bajorin DF, Scher HI, et al. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol 1999; 161:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/42\">",
"      Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/43\">",
"      Tsuji M, Kojima K, Murakami Y, et al. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997; 79:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/44\">",
"      Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/45\">",
"      Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41992/abstract/46\">",
"      Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011; 12:137.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2991 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41992=[""].join("\n");
var outline_f41_0_41992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210939004\">",
"      OVERVIEW OF TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210940763\">",
"      PATIENTS UNDERGOING RADICAL CYSTECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H210939438\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H971959904\">",
"      - MVAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H971959911\">",
"      - CMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H971959918\">",
"      - GC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1244259799\">",
"      Neoadjuvant radiation therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H501917112\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210940253\">",
"      PATIENTS DESIRING BLADDER PRESERVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H501917562\">",
"      Primary chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H618709098\">",
"      - Is there a role for additional chemotherapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15490168\">",
"      Follow-up after chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618709291\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210940629\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210941663\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      p53 status for risk-directed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1837314600\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=related_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41993="Techniques for ripening the unfavorable cervix prior to induction";
var content_f41_0_41993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques for ripening the unfavorable cervix prior to induction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Deborah A Wing, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/0/41993/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/0/41993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical status is a good predictor of the likelihood of vaginal delivery when labor is induced. Any induction method is likely to be effective in a woman with a favorable cervix, whereas no method is highly successful when performed in a woman with a cervix that is firm, posterior, and neither dilated nor effaced. Therefore, if the cervix is unfavorable, a ripening process is generally employed prior to induction.",
"   </p>",
"   <p>",
"    Cervical ripening is a complex process that results in physical softening and distensibility of the cervix, ultimately leading to partial cervical effacement and dilatation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Remodeling of the cervix involves enzymatic dissolution of collagen fibrils, increase in water content, and chemical changes (",
"    <a class=\"graphic graphic_figure graphicRef80354 \" href=\"mobipreview.htm?39/60/40896\">",
"     figure 1",
"    </a>",
"    ). These changes are induced by hormones (estrogen, progesterone, relaxin), as well as cytokines, prostaglandins, and nitric oxide synthesis enzymes.",
"   </p>",
"   <p>",
"    The two major techniques for iatrogenic cervical ripening are (1) mechanical (physical) interventions, such as insertion of catheters or cervical dilators, and (2) application of cervical ripening agents, such as prostaglandins. These techniques will be reviewed below. General issues regarding induction of labor and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF AVAILABLE DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of available data on cervical ripening is hindered by several factors, which make it difficult to determine the methods of cervical ripening and labor induction, either used alone or in combination, that are most effective. These factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A basic lack of understanding of the physiologic events that initiate and sustain labor",
"     </li>",
"     <li>",
"      Wide biologic variation in the progress of normal labor",
"     </li>",
"     <li>",
"      Failure to distinguish between cervical ripening and labor induction",
"     </li>",
"     <li>",
"      Use of different clinical endpoints in research studies (eg, change in cervix verus length of labor versus route of delivery)",
"     </li>",
"     <li>",
"      A lack of trials comparing multiple methods",
"     </li>",
"     <li>",
"      Inadequate data on patient satisfaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is relatively easy for investigators to report changes in Bishop scores (",
"    <a class=\"graphic graphic_table graphicRef65320 \" href=\"mobipreview.htm?26/41/27291\">",
"     table 1",
"    </a>",
"    ) as an objective measure of the effect of an intervention on cervical ripening, the Bishop score itself is not a clinically important outcome: it is useful only to the extent that it predicts the outcome of labor induction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H12#H12\">",
"     \"Principles of labor induction\", section on 'Bishop score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003895\">",
"    <span class=\"h1\">",
"     PROSTAGLANDINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of prostaglandins causes dissolution of collagen bundles and an increase in the submucosal water content of the cervix. These changes lead to a cervical state that is associated with greater success when labor is induced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/4\">",
"     4",
"    </a>",
"    ]. Prostaglandins also cause the uterus to contract, and may initiate labor.",
"   </p>",
"   <p>",
"    Prostaglandins are our preferred method of cervical ripening in women with an unscarred uterus. As discussed below, there are strong data from placebo-controlled randomized trials supporting their efficacy. Because contractions are often initiated, prostaglandin use reduces the need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for augmentation or induction of labor, which is an advantage of this approach over use of balloon catheters (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Balloon catheter'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/5\">",
"     5",
"    </a>",
"    ]. Administering prostaglandins is also easier than inserting a balloon catheter. Finally, in our experience, patients are more satisfied with cervical ripening by prostaglandins than by balloon catheters.",
"   </p>",
"   <p>",
"    Although excessive uterine activity is a disadvantage of prostaglandin use, these agents have a good safety profile in women with unscarred uteruses: the rates of low Apgar score, neonatal intensive care unit admission, meconium staining, and cesarean delivery are equivalent to the rates associated with use of balloon catheters for cervical ripening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our preferred prostaglandin for cervical ripening is prostaglandin E1 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) administered vaginally (see",
"    <a class=\"local\" href=\"#H92003909\">",
"     'Prostaglandin E1 (misoprostol)'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2274813\">",
"    <span class=\"h2\">",
"     Evidence of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have established that prostaglandins are effective for both cervical ripening and labor induction; however, the distinction between cervical ripening and formal induction has not always been clearly made in these trials. In a Cochrane review that included a heterogeneous group of women, compared to",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment, use of PGE2 (all regimens) resulted in a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower risk of continuing to have an unfavorable cervix after 12 to 24 hours (RR 0.46, 95% CI 0.35-0.62; 5 trials, 467 women)",
"     </li>",
"     <li>",
"      Lower need for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation (RR 0.83, 95% CI 0.73-0.94; 12 trials, 1321 women)",
"     </li>",
"     <li>",
"      Lower rate of failing to achieve a vaginal delivery within 24 hours (RR 0.19, 95% CI 0.14-0.25; 2 trials, 384 women)",
"     </li>",
"     <li>",
"      The rate of cesarean delivery was modestly reduced (RR 0.89, 95% CI 0.79-1.00; 34 trials, 6399 women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5354331\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal type, route, frequency, and dose of prostaglandins for cervical ripening have not been determined. Prostaglandin analogs were originally given by intravenous and oral routes. Subsequently, local administration of prostaglandins to the vagina or the endocervix became the preferred route because the frequency of side effects could be reduced by local administration, while maintaining an acceptable clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Intracervical PGE2 is somewhat less effective than intravaginal PGE2 for achieving vaginal delivery within 24 hours (RR of not achieving vaginal delivery 1.26, 95% CI 1.12-1.41), but both preparations appear to result in similar rates of cesarean delivery and tachysystole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/9\">",
"     9",
"    </a>",
"    ]. Our preference is to use PGE1 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) administered vaginally (see",
"    <a class=\"local\" href=\"#H92003909\">",
"     'Prostaglandin E1 (misoprostol)'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Uterine activity and fetal heart rate monitoring are indicated for at least 30 minutes after administration of prostaglandins for cervical ripening, and should be maintained as long as regular uterine activity is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If labor does not ensue or is not progressing adequately after administering prostaglandins, repeated doses can be given. Alternatively,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    may be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H7537379#H7537379\">",
"     \"Principles of labor induction\", section on 'Oxytocin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2276848\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins are not used for cervical ripening or labor induction in term pregnancies with a prior cesarean birth or other prior major uterine surgeries (eg, extensive myomectomies and hysterotomies) because of the increased risk for uterine rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=see_link\">",
"     \"Cervical ripening and induction of labor in women with a prior cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277345\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of prostaglandins include tachysystole, fever, chills, vomiting, and diarrhea. The frequency of these side effects depends on the type of prostaglandin, dose, and route of administration. Uterine contractile abnormalities are encountered in up to 30 percent of cases depending on the vehicle and route of administration; other systemic effects occur in up to 5 percent of cases. Treatment of maternal discomfort is supportive; management of tachysystole is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H26#H26\">",
"     \"Principles of labor induction\", section on 'Tachysystole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although comparative trials using prostaglandins have not reported changes in the rate of adverse perinatal outcomes, these reports have been of insufficient size to exclude the possibility of uncommon serious side effects, such as uterine rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003902\">",
"    <span class=\"h2\">",
"     Prostaglandin E2",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two prostaglandin E2 preparations commercially available for cervical ripening in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2274829\">",
"    <span class=\"h3\">",
"     Prepidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepidil&reg;",
"    <strong>",
"    </strong>",
"    contains 0.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    in 2.5 mL of gel for intracervical administration. The dose can be repeated in 6 to 12 hours if cervical change is inadequate and uterine activity is minimal following the first dose. The manufacturer recommends that the maximum cumulative dose of dinoprostone not exceed 1.5 mg (ie, three doses) within a 24-hour period.",
"    <br/>",
"    <br/>",
"    The time interval between the final dose and initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    should be 6 to 12 hours because of the potential for uterine tachysystole with concurrent oxytocin and prostaglandin administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H25#H25\">",
"     \"Principles of labor induction\", section on 'Complications and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2274844\">",
"    <span class=\"h3\">",
"     Cervidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervidil&reg; is a vaginal insert containing 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    in a timed-release formulation (the medication is released at 0.3",
"    <span class=\"nowrap\">",
"     mg/h).",
"    </span>",
"    The insert is left in place until active labor begins, or for 12 hours.",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    may be initiated anytime beyond 30 minutes after removal of the insert.",
"    <br/>",
"   </p>",
"   <p>",
"    An advantage of the vaginal insert over the gel formulation is that the vaginal insert can be removed in cases of uterine tachysystole or abnormalities of the fetal heart rate tracing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003909\">",
"    <span class=\"h2\">",
"     Prostaglandin E1 (misoprostol)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    (Cytotec&reg;) is a prostaglandin E1 analog available as 100 mcg and 200 mcg tablets, which can be broken to provide 25 mcg or 50 mcg aliquots. Consistency in dosing can be maintained by weighing the tablet fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is stored at room temperature, rapidly absorbed from both the oral and vaginal routes, and associated with few systemic side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approved indication for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is treatment and prevention of gastric ulcer disease related to chronic nonsteroidal antiinflammatory drug use; administration of this drug for cervical ripening and labor induction is considered an off-label, investigational use in the United States. However, there is sufficient evidence that it is an effective alternative to prostaglandin E2 preparations for cervical ripening and labor induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists (ACOG) has indicated that use of misoprostol appears safe and efficacious when used as a cervical ripening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    labor induction agent when utilized as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003916\">",
"    <span class=\"h3\">",
"     Vaginal administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women with intact membranes and an unfavorable cervix, meta-analyses have found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to",
"      <span class=\"nowrap\">",
"       placebo/no",
"      </span>",
"      treatment,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (given vaginally) significantly improved the rate of vaginal delivery within 24 hours (vaginal delivery not achieved in 24 hours: RR 0.40, 95% CI 0.22-0.70; 2 trials, 112 women) and cervical ripening (cervix unfavorable after 12 to 24 hours: RR 0.10, 95% CI 0.01-0.64; 2 trials, 107 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      (given vaginally) was more effective than other prostaglandins given vaginally for labor induction: the risk of failure to achieve vaginal delivery within 12 and 24 hours was lower with misoprostol (failure to deliver with 24 hours, RR 0.78, 95% CI 0.67-0.91; 8 trials, 1995 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      augmentation was used less often with misoprostol than with other vaginal prostaglandins (RR 0.69, 95% CI 0.56-0.86; 10 trials, 2276 women).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      (given vaginally) was more effective than other prostaglandins given intracervically. Failure to achieve vaginal delivery within 24 hours (RR 0.64, 95% CI 0.56-0.73; 8 trials, 1088 women) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation were both reduced with misoprostol (RR 0.53, 95% CI 0.43-0.67; 10 trials, 1075 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      did not result in a significant reduction in the cesarean delivery rate compared to other (vaginal or intracervical) prostaglandins and was consistently associated with a higher rate of uterine tachysystole with fetal heart rate changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      (given vaginally) was more effective than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      for induction of labor (RR of failure to achieve vaginal delivery within 24 hours 0.53; 95% CI 0.33-0.84; 1 trial, 140 women) and in reducing the cesarean delivery rate (RR 0.58, 95% CI 0.37-0.90; 5 trials, 736 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Uterine tachysystole without associated fetal heart rate changes was more common with misoprostol than oxytocin (RR 3.0, 95% CI 1.48&ndash;6.07; 1 trial, 210 women), but tachysystole with fetal heart rate changes was not increased (RR 0.75, 95% CI 0.17-3.27; 1 trial, 210 women). There were no clear differences between drugs in perinatal or maternal adverse outcomes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      (given vaginally) and balloon catheters resulted in similar times to delivery, cesarean rates, and risks of chorioamnionitis, but misoprostol resulted in a three-fold higher rate of tachysystole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2276838\">",
"    <span class=\"h4\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose and timing interval of intravaginally applied",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17,21-24\">",
"     17,21-24",
"    </a>",
"    ]. A meta-analysis reported that the 50 mcg dose was more effective than 25 mcg (eg, higher rates of delivery after a single dose and delivery within 24 hours, and a lower rate of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    use), but the safety of the higher dose could not be adequately evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, lower doses, such as 25 mcg, should be used initially, with re-dosing intervals of three to six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ]. We administer 25 mcg every three to four hours. The World Health Organization (WHO) suggests 25 mcg every six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    50 mcg at six-hour intervals may be appropriate in some situations, such as inadequate uterine activity at lower doses; however, this dose is associated with a higher risk of tachysystole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    may be initiated, if necessary, four hours after the final",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    dose.",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    vaginal insert consisting of a controlled-release, retrievable polymer chip for gradual delivery of misoprostol into the vagina is under investigation. It is not commercially available; dose-ranging studies are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003930\">",
"    <span class=\"h3\">",
"     Oral administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for cervical ripening and labor induction has also been explored. It is convenient and effective, but direct comparisons with other routes of administration are difficult because of the large variety of regimens that have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/16\">",
"     16",
"    </a>",
"    ]. The concentration of orally administered misoprostol peaks sooner and declines more rapidly than with vaginal administration (",
"    <a class=\"graphic graphic_figure graphicRef71621 \" href=\"mobipreview.htm?7/16/7438\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59851 \" href=\"mobipreview.htm?4/46/4843\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/15\">",
"     15",
"    </a>",
"    ]. We do not use misoprostol orally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2276919\">",
"    <span class=\"h4\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the large number of trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for cervical ripening or labor induction, there is no consensus as to the optimum oral dose, dosing interval, or maximum number of doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/16,32,33\">",
"     16,32,33",
"    </a>",
"    ]. One reasonable option for a conservative, low-dose regimen is 50 mcg orally no more frequently than every four hours, with a maximum of six consecutive doses. The WHO suggests 25 mcg every two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Titration of the oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    dose is another option. Two randomized trials found that oral misoprostol in doses titrated to achieve adequate contractions resulted in outcomes (rates of vaginal delivery within 24 hours, cesarean delivery, and tachysystole) similar to those with vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    and avoided the high rate of tachysystole associated with traditional dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, both trials noted that the randomization to delivery interval was three to four hours longer in women induced with oral misoprostol. Low doses of oral misoprostol were achieved by making a solution (eg, dissolving a 200 mcg tablet in 200 mL tap water), as this was believed to provide more accurate dosing than simply cutting the tablet into pieces. Because oral dosing has short (two-hour) duration of action, administration was repeated at two-hour intervals.",
"   </p>",
"   <p>",
"    The authors of a systematic review on use of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    concluded low-dose oral misoprostol solution (20 mcg) administered every two hours was at least as effective as vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    and vaginal misoprostol, with lower rates of cesarean delivery and uterine hyperstimulation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared to dinoprostone, misoprostol has the advantage of availability in areas where refrigeration is not available. It should be noted, however, that the trials in which the oral route was used were not of sufficient sample size to fully address maternal or neonatal safety outcome measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92003937\">",
"    <span class=\"h3\">",
"     Buccal or sublingual administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other novel approaches to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , including buccal and sublingual administration, have been described, but are less well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. These routes of administration may avoid first pass hepatic metabolism associated with oral ingestion, and may therefore increase bioavailability similar to that achieved with vaginal administration. Pharmacokinetic data support the hypothesis that buccal and sublingual routes of administration are associated with more rapid onset of action and greater bioavailability than other routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/36\">",
"     36",
"    </a>",
"    ]. Additionally, it is hypothesized that administration using these routes may avoid direct uterine effects, such as tachysystole.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sublingual versus oral: A randomized trial assigned 250 women to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      50 mcg sublingually or misoprostol 100 mcg orally every four hours to a maximum of five doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/38\">",
"       38",
"      </a>",
"      ]. Both routes had similar efficacy in achieving vaginal delivery within 24 hours and similar rates of uterine tachysystole.",
"     </li>",
"     <li>",
"      Sublingual versus vaginal: A meta-analysis of five randomized trials that compared sublingual",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      to vaginal misoprostol for induction found no significant difference between routes in rate of vaginal delivery within 24 hours, uterine tachysystole, or need for cesarean delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are needed to clarify the efficacy and safety of buccal and sublingual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    use; its use when administered in these ways is considered experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194729129\">",
"    <span class=\"h3\">",
"     Combination therapy with mechanical methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"local\" href=\"#H2277400\">",
"     'Balloon catheter combined with uterotonic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANICAL METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical methods are among the oldest approaches used to promote cervical ripening. Advantages of these techniques compared with pharmacologic methods include their low cost compared with some drugs, low risk of tachysystole, few systemic side effects, and convenient storage requirements (no refrigeration or expiration, which are issues for some drugs). Disadvantages include a possible small increase in the risk of maternal and neonatal infection from introduction of a foreign body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/41\">",
"     41",
"    </a>",
"    ], the potential for disruption of a low-lying placenta, some maternal discomfort upon manipulation of the cervix, and frequent need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    induction of labor.",
"   </p>",
"   <p>",
"    The most common mechanical methods are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insertion of a balloon catheter",
"     </li>",
"     <li>",
"      Placement of hygroscopic dilators within the endocervical canal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These methods likely work, at least in part, by causing the release of prostaglandin F2-alpha from the decidua and adjacent membranes or prostaglandin E2 from the cervix. In addition, insertion of a catheter or dilator directly dilates the cervix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Balloon catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double balloon catheter specifically designed for cervical ripening is commercially available (",
"    <a class=\"graphic graphic_figure graphicRef61707 \" href=\"mobipreview.htm?19/19/19770\">",
"     figure 3",
"    </a>",
"    ); alternatively, a Foley catheter can be used. Randomized trials have reported equivalent clinical outcomes for the two types of catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277222\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our patients undergo continuous uterine activity monitoring while the balloon catheter is in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13846255\">",
"    <span class=\"h4\">",
"     Foley catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ring forceps are used to pass a deflated Foley catheter (#16 with the tip removed and a 30 to 80 mL balloon) through the internal cervical os and into the extraamniotic space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Alternatively, the catheter can be inserted manually, similar to an intrauterine pressure catheter. This is usually possible even if the cervix is not dilated since the pregnant cervix is soft and distensible and rarely tightly closed. If it is difficult to pass the catheter, a urologic sound can be placed inside it and used to direct placement. After the sound has been removed, the balloon is distended with saline and retracted so that it rests against the internal os. Some clinicians attach a weight (eg, one liter of fluid) to the end of the catheter and suspend it from the end of the bed, but weighted traction on the inflated balloon has not been proven to enhance cervical ripening.",
"   </p>",
"   <p>",
"    The catheter is left in place until it is extruded or for up to 12 hours.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is begun after the catheter has been extruded or removed. A randomized trial found that removing non-extruded catheters after 12 hours and beginning oxytocin resulted in significantly more vaginal deliveries within 24 hours than waiting 24 hours before removal and oxytocin induction (60 versus 21 percent), and did not lead to an increased risk of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large Foley balloon catheter may be more effective than a small one. In a study that compared 30 mL with 60 mL Foley balloon inflation for labor induction and the effect on length of labor and mode of delivery, a significantly higher proportion of women who received 60 mL Foley balloons achieved delivery within 12 hours of placement compared with the 30 mL Foley balloon group (26 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/45\">",
"     45",
"    </a>",
"    ]. There was no difference in median time interval to delivery or proportion of women who achieved delivery within 24 hours, although the median cervical dilation after Foley balloon expulsion was significantly higher in the 60 mL Foley balloon group (4 versus 3 cm). There were no differences in the frequencies of cesarean delivery, maternal morbidity, or neonatal outcomes. If the balloon is filled to 60 mL, an appropriate large gauge catheter should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13846262\">",
"    <span class=\"h4\">",
"     Double balloon catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for inserting a double balloon catheter is similar to that described for the single balloon catheter. The catheter is inserted until the proximal balloon is in the cervical canal; the distal balloon should be intrauterine. The intrauterine balloon is inflated with 40 mL saline and pulled back to abut the internal os. The proximal balloon should now be outside the external os and is inflated with 20 mL saline. If the balloons are correctly situated on either end of the cervix, the balloons can be inflated with up to 80 mL saline per balloon.",
"   </p>",
"   <p>",
"    In comparative trials, there were no clinically important differences in outcomes with use of a double versus a single balloon catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277229\">",
"    <span class=\"h3\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of balloon catheters has been associated with a mean change in Bishop score of 3.3 to 5.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/47\">",
"     47",
"    </a>",
"    ]. In a small placebo-controlled randomized trial, use of a balloon catheter resulted in fewer",
"    <span class=\"nowrap\">",
"     unfavorable/unchanged",
"    </span>",
"    cervixes after 12 to 24 hours (RR 0.07, 95% CI 0.03-0.19) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have generally reported that use of a balloon catheter is as effective for cervical ripening as prostaglandins, which are of proven efficacy (see",
"    <a class=\"local\" href=\"#H92003895\">",
"     'Prostaglandins'",
"    </a>",
"    above). In a meta-analysis of randomized trials comparing use of a balloon catheter versus a prostaglandin (vaginal and intracervical prostaglandin E2 [PGE2],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) for cervical ripening and induction of labor, the following were among the major findings reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"     48",
"    </a>",
"    ]. Compared to prostaglandins, balloon catheters resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trend toward a higher rate of vaginal delivery not achieved within 24 hours (RR 1.26, 95% CI 0.94-1.68; 7 trials, 1142 women)",
"     </li>",
"     <li>",
"      A similar rate of cesarean delivery (RR 1.01, 95% CI 0.90-1.13; 21 trials, 3202 women)",
"     </li>",
"     <li>",
"      A similar rate of patients with cervix",
"      <span class=\"nowrap\">",
"       unfavorable/unchanged",
"      </span>",
"      after 12 to 24 hours (RR 0.96, 95% CI 0.70-1.34; 2 trials, 219 women)",
"     </li>",
"     <li>",
"      A higher rate of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation (RR 1.51, 95% CI 1.15-1.97; 6 trials, 613 women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major advantage of using a balloon catheter over prostaglandins is the substantial reduction in hyperstimulation (tachysystole) with fetal heart rate changes, which is clinically important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperstimulation with fetal heart rate changes (RR 0.19, 95% CI 0.08-0.43; 9 trials, 1931 women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperstimulation without fetal heart rate changes is less clinically important and trended lower, as well (RR 0.78, 95% CI 0.26-2.33; 11 trials, 1578 women).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277316\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, the insertion of a foreign object could increase the risk of intrauterine infection, but data from the meta-analysis discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"     48",
"    </a>",
"    ] did not show evidence of an increased risk of infectious morbidity in mothers or neonates exposed to mechanical methods of cervical ripening versus prostaglandins. In general, these trials typically excluded women with ruptured membranes. Severe infection or sepsis related to use of a balloon catheter for cervical ripening has not been reported; however, this cannot be considered reassuring since most clinicians avoid use of mechanical cervical ripening methods in women at high risk of infection (eg, premature rupture of membranes, immunocompromise). &nbsp;",
"   </p>",
"   <p>",
"    There are no data specifically looking at risk of infection with respect to duration of ruptured membranes before",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after insertion of a balloon catheter. Some practitioners do not place balloon catheters in women with ruptured membranes, some remove the catheter if membranes rupture at any time after placement, others limit the duration of cervical ripening to 12 hours if membranes rupture after placement. There is no consensus on optimal management in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277400\">",
"    <span class=\"h3\">",
"     Balloon catheter combined with uterotonic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not use concurrent therapies.",
"   </p>",
"   <p>",
"    There are some data from a meta-analysis of randomized trials that concurrent therapy using a balloon catheter and prostaglandins accelerates cervical change compared with pharmacotherapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to prostaglandins alone, the combination of a balloon catheter and a prostaglandin resulted in fewer cervixes that were",
"      <span class=\"nowrap\">",
"       unfavorable/unchanged",
"      </span>",
"      after 12 to 24 hours (RR 0.46, 95% CI 0.32-0.65; 2 trials, 249 women), fewer failures to vaginal delivery within 24 hours (RR 0.45, 95% CI 0.28-0.71; 3 trials, 698 women), but a similar cesarean delivery rate (RR 0.92, 95% CI 0.79-1.08; 8 trials, 1295 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no trials of use of a balloon catheter and prostaglandins compared with use of a catheter alone.",
"   </p>",
"   <p>",
"    Combined therapy (a balloon catheter and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    ) does not appear to have any benefits compared with use of a catheter alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to use of a balloon catheter alone, the combined use of a balloon catheter and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      did not shorten the time to delivery and had no effect on the likelihood of delivery within 24 hours or vaginal delivery rate in a randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Catheter and infusion of extra-amniotic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraamniotic saline infusion (EASI) is a procedure in which sterile saline is infused continuously via a catheter placed in the extraamniotic space. It is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/50-53\">",
"     50-53",
"    </a>",
"    ], but has no clear advantage over other methods (balloon catheter alone, prostaglandins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48,54-56\">",
"     48,54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hygroscopic dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of hygroscopic dilators: one is made from natural seaweed (laminaria tents) and the other is a synthetic product (eg, Dilapan-S&trade;). Hygroscopic dilators are safe and effective for dilating the cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/57\">",
"     57",
"    </a>",
"    ], although they are used primarily during pregnancy termination rather than for preinduction cervical ripening of term pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pregnancy termination\", section on 'Cervical preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hygroscopic dilators are designed to absorb moisture and thus gradually expand within the cervical canal. They probably function by disrupting the chorioamniotic decidual interface, causing lysosomal destruction and prostaglandin release. These events lead to active stretching of the cervix beyond the passive mechanical stretching provided by the tent itself.",
"   </p>",
"   <p>",
"    Some clinicians prefer to use hygroscopic dilators rather than balloon catheters in patients with a prior cesarean delivery who are scheduled for induction of labor. There is no evidence to recommend one approach over the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277617\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion of a large number of small diameter hygroscopic dilators (2 or 3 mm) is preferable to using a few large ones (6 mm) because placement is easier and results in greater cervical dilation. After prepping the cervix and vagina with an antiseptic, the cervix is held with a nontraumatic clamp, if necessary, and as many dilators as possible are inserted into the endocervical canal without using excessive force; some cramping is common. Dipping the laminaria in a sterile lubricant before insertion may facilitate placement. The dilators can be packed in place with two 4- by 4-inch gauze sponges tucked into the fornices, and the number of dilators and gauze sponges that were inserted should be recorded in the patient&rsquo;s chart.",
"   </p>",
"   <p>",
"    Laminaria are removed 12 to 24 hours after placement, whereas synthetic dilators can be removed sooner, after 6 to 8 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2277624\">",
"    <span class=\"h3\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized trials comparing use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or a prostaglandin plus hygroscopic dilators with use of oxytocin or a prostaglandin alone found statistically similar rates of cesarean delivery whether or not hygroscopic dilators were used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"     48",
"    </a>",
"    ]. In placebo-controlled trials of hygroscopic dilators, use of dilators did not reduce the rate of cesarean delivery (RR 1.00, 95% CI 0.76-1.30) or failure to deliver vaginally within 24 hours (RR 0.90, 95% CI 0.64-1.26).",
"   </p>",
"   <p>",
"    These data suggest that although hygroscopic dilators can dilate the cervix, they are inadequate for improving the outcome of induction. However, no large trials have been performed and there are no good comparative studies evaluating the optimal use of hygroscopic dilators with other modalities, such as amniotomy, to improve the rate of successful induction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2278937\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drawback of hygroscopic dilator and laminaria usage is the theoretic potential for a higher incidence of postpartum maternal and fetal infections as compared to prostaglandin administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/60-62\">",
"     60-62",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/63-71\">",
"     63-71",
"    </a>",
"    ], nitric oxide (NO) donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/72\">",
"     72",
"    </a>",
"    ], hyaluronidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/73\">",
"     73",
"    </a>",
"    ], corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/74\">",
"     74",
"    </a>",
"    ], castor oil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/75\">",
"     75",
"    </a>",
"    ], sexual intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], breast stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/78\">",
"     78",
"    </a>",
"    ], and herbal preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/79\">",
"     79",
"    </a>",
"    ] have been used for cervical ripening with varying degrees of success. We do not use these drugs because of limited data regarding safety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    efficacy, and the availability of proven alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13846292\">",
"    <span class=\"h1\">",
"     FETAL DEMISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical ripening and induction of labor in cases of intrauterine fetal demise is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=see_link\">",
"     \"Diagnosis and management of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTPATIENT CERVICAL RIPENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient approaches to cervical ripening and labor induction for elective or marginal indications could be useful in reducing the duration of hospitalization and the staffing requirements of labor and delivery. The available body of evidence is insufficient to support a recommendation for the most effective and safest approach, but suggests that it is feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Published studies reflect a variety of different approaches to cervical ripening, including local applications of prostaglandin compounds and placement of Foley balloon catheters to the lower uterine segment with or without immediate hospitalization for further labor management. To adequately address safety of any outpatient cervical ripening and labor induction technique, large numbers of subjects will be necessary. For this reason, we do not recommend outpatient cervical ripening and labor induction at this time, other than in a research setting.",
"   </p>",
"   <p>",
"    If outpatient cervical ripening with prostaglandins is performed, uterine activity and fetal heart rate monitoring are indicated for at least 30 minutes after administration, and should be maintained as long as regular uterine activity is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/0/41993/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal methods for cervical ripening and labor induction have yet to be identified. Clinical studies of human parturition are hindered by a lack of understanding of the physiologic events that initiate and sustain labor. There is wide biologic variation among pregnant women in the progress of normal labor and iatrogenic variation in the management of labor and labor induction; this makes the investigation of new uterotonic agents difficult. Although data from randomized trials comparing two cervical ripening approaches are available, there are insufficient comparative data to determine which of several methods is the most effective and offers the best safety profile. Variation in indications for induction, parity, and gestational age at induction, as well as other demographic features, undoubtedly affects clinical results. A randomized trial of sufficient size to reliably assess the efficacy, safety, patient satisfaction, and cost of the various options is needed, but may never be conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20153268\">",
"    <span class=\"h2\">",
"     Unfavorable cervix",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are scheduled for labor induction and have an unfavorable cervix, clinical outcomes are similar whether prostaglandins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , or transcervical Foley balloon catheter placement is used for cervical ripening. Use of the latter is associated with less uterine overactivity than the pharmacological approaches.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest prostaglandins for cervical ripening (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H92003895\">",
"       'Prostaglandins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      over other prostaglandins (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An appropriate dose is 25 mcg intravaginally every three to six hours.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      , if required, can be started four hours after the last misoprostol dose.",
"      <br/>",
"      <br/>",
"      Uterine tachysystole with fetal heart rate changes appears to be more common with misoprostol than with other prostaglandins, but this is not associated with an increased risk of adverse perinatal outcomes. (See",
"      <a class=\"local\" href=\"#H92003909\">",
"       'Prostaglandin E1 (misoprostol)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a balloon catheter for cervical ripening is a reasonable alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Balloon catheter'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Favorable cervix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most induction methods are effective in women with favorable cervices. Cervical ripening is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H11#H11\">",
"     \"Principles of labor induction\", section on 'Predicting a successful induction'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/1\">",
"      Maul H, Mackay L, Garfield RE. Cervical ripening: biochemical, molecular, and clinical considerations. Clin Obstet Gynecol 2006; 49:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/2\">",
"      Word RA, Li XH, Hnat M, Carrick K. Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts. Semin Reprod Med 2007; 25:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/3\">",
"      Timmons BC, Mahendroo M. Processes regulating cervical ripening differ from cervical dilation and postpartum repair: insights from gene expression studies. Reprod Sci 2007; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/4\">",
"      Keirse MJ. Natural prostaglandins for induction of labor and preinduction cervical ripening. Clin Obstet Gynecol 2006; 49:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/5\">",
"      Vaknin Z, Kurzweil Y, Sherman D. Foley catheter balloon vs locally applied prostaglandins for cervical ripening and labor induction: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/6\">",
"      Kelly AJ, Malik S, Smith L, et al. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2009; :CD003101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/7\">",
"      Keirse MJ. Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience. J Reprod Med 1993; 38:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/8\">",
"      Prins RP, Neilson DR Jr, Bolton RN, et al. Preinduction cervical ripening with sequential use of prostaglandin E2 gel. Am J Obstet Gynecol 1986; 154:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/9\">",
"      Boulvain M, Kelly A, Irion O. Intracervical prostaglandins for induction of labour. Cochrane Database Syst Rev 2008; :CD006971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/10\">",
"      ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/11\">",
"      Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med 2001; 345:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/12\">",
"      Smith CV, Rayburn WF, Miller AM. Intravaginal prostaglandin E2 for cervical ripening and initiation of labor. Comparison of a multidose gel and single, controlled-release pessary. J Reprod Med 1994; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/13\">",
"      Witter FR, Rocco LE, Johnson TR. A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term. Am J Obstet Gynecol 1992; 166:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/14\">",
"      Williams MC, Tsibris JC, Davis G, et al. Dose variation that is associated with approximated one-quarter tablet doses of misoprostol. Am J Obstet Gynecol 2002; 187:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/15\">",
"      Khan RU, El-Refaey H, Sharma S, et al. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol 2004; 103:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/16\">",
"      Alfirevic Z, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2006; :CD001338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/17\">",
"      Hofmeyr GJ, G&uuml;lmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010; :CD000941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/18\">",
"      Austin SC, Sanchez-Ramos L, Adair CD. Labor induction with intravaginal misoprostol compared with the dinoprostone vaginal insert: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 202:624.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/19\">",
"      Fox NS, Saltzman DH, Roman AS, et al. Intravaginal misoprostol versus Foley catheter for labour induction: a meta-analysis. BJOG 2011; 118:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/20\">",
"      Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2004; :CD004221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/21\">",
"      Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997; 177:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/22\">",
"      Farah LA, Sanchez-Ramos L, Rosa C, et al. Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction. Am J Obstet Gynecol 1997; 177:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/23\">",
"      Wing DA. Labor induction with misoprostol. Am J Obstet Gynecol 1999; 181:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/24\">",
"      Sanchez-Ramos L, Kaunitz AM, Wears RL, et al. Misoprostol for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol 1997; 89:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/25\">",
"      Sanchez-Ramos L, Kaunitz AM, Delke I. Labor induction with 25 microg versus 50 microg intravaginal misoprostol: a systematic review. Obstet Gynecol 2002; 99:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/26\">",
"      Calder AA, Loughney AD, Weir CJ, Barber JW. Induction of labour in nulliparous and multiparous women: a UK, multicentre, open-label study of intravaginal misoprostol in comparison with dinoprostone. BJOG 2008; 115:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/27\">",
"      Tan TC, Yan SY, Chua TM, et al. A randomised controlled trial of low-dose misoprostol and dinoprostone vaginal pessaries for cervical priming. BJOG 2010; 117:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/28\">",
"      Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/29\">",
"      Wing DA, Misoprostol Vaginal Insert Consortium. Misoprostol vaginal insert compared with dinoprostone vaginal insert: a randomized controlled trial. Obstet Gynecol 2008; 112:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/30\">",
"      Wing DA, Powers BL, Rayburn WF. Determining dose and endpoints of a controlled-release misoprostol vaginal insert for a phase III trial. J Reprod Med 2008; 53:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/31\">",
"      Wing DA, Miller H, Parker L, et al. Misoprostol vaginal insert for successful labor induction: a randomized controlled trial. Obstet Gynecol 2011; 117:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/32\">",
"      Wing DA, Park MR, Paul RH. A randomized comparison of oral and intravaginal misoprostol for labor induction. Obstet Gynecol 2000; 95:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/33\">",
"      Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labor: a systematic review. Obstet Gynecol 2009; 113:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/34\">",
"      Hofmeyr GJ, Alfirevic Z, Matonhodze B, et al. Titrated oral misoprostol solution for induction of labour: a multi-centre, randomised trial. BJOG 2001; 108:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/35\">",
"      D&auml;llenbach P, Boulvain M, Viardot C, Irion O. Oral misoprostol or vaginal dinoprostone for labor induction: a randomized controlled trial. Am J Obstet Gynecol 2003; 188:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/36\">",
"      Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/37\">",
"      Wolf SB, Sanchez-Ramos L, Kaunitz AM. Sublingual misoprostol for labor induction: a randomized clinical trial. Obstet Gynecol 2005; 105:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/38\">",
"      Shetty A, Mackie L, Danielian P, et al. Sublingual compared with oral misoprostol in term labour induction: a randomised controlled trial. BJOG 2002; 109:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/39\">",
"      Shetty A, Danielian P, Templeton A. Sublingual misoprostol for the induction of labor at term. Am J Obstet Gynecol 2002; 186:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/40\">",
"      Souza AS, Amorim MM, Feitosa FE. Comparison of sublingual versus vaginal misoprostol for the induction of labour: a systematic review. BJOG 2008; 115:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/41\">",
"      Heinemann J, Gillen G, Sanchez-Ramos L, Kaunitz AM. Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review. Am J Obstet Gynecol 2008; 199:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/42\">",
"      Pennell CE, Henderson JJ, O'Neill MJ, et al. Induction of labour in nulliparous women with an unfavourable cervix: a randomised controlled trial comparing double and single balloon catheters and PGE2 gel. BJOG 2009; 116:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/43\">",
"      Salim R, Zafran N, Nachum Z, et al. Single-balloon compared with double-balloon catheters for induction of labor: a randomized controlled trial. Obstet Gynecol 2011; 118:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/44\">",
"      Levy R, Kanengiser B, Furman B, et al. A randomized trial comparing a 30-mL and an 80-mL Foley catheter balloon for preinduction cervical ripening. Am J Obstet Gynecol 2004; 191:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/45\">",
"      Delaney S, Shaffer BL, Cheng YW, et al. Labor induction with a Foley balloon inflated to 30 mL compared with 60 mL: a randomized controlled trial. Obstet Gynecol 2010; 115:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/46\">",
"      Cromi A, Ghezzi F, Agosti M, et al. Is transcervical Foley catheter actually slower than prostaglandins in ripening the cervix? A randomized study. Am J Obstet Gynecol 2011; 204:338.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/47\">",
"      Gelber S, Sciscione A. Mechanical methods of cervical ripening and labor induction. Clin Obstet Gynecol 2006; 49:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/48\">",
"      Jozwiak M, Bloemenkamp KW, Kelly AJ, et al. Mechanical methods for induction of labour. Cochrane Database Syst Rev 2012; 3:CD001233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/49\">",
"      Pettker CM, Pocock SB, Smok DP, et al. Transcervical Foley catheter with and without oxytocin for cervical ripening: a randomized controlled trial. Obstet Gynecol 2008; 111:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/50\">",
"      Lyndrup J, Nickelsen C, Weber T, et al. Induction of labour by balloon catheter with extra-amniotic saline infusion (BCEAS): a randomised comparison with PGE2 vaginal pessaries. Eur J Obstet Gynecol Reprod Biol 1994; 53:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/51\">",
"      Vengalil SR, Guinn DA, Olabi NF, et al. A randomized trial of misoprostol and extra-amniotic saline infusion for cervical ripening and labor induction. Obstet Gynecol 1998; 91:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/52\">",
"      Yuen PM, Pang HY, Chung T, Chang A. Cervical ripening before induction of labour in patients with an unfavourable cervix: a comparative randomized study of the Atad Ripener Device, prostaglandin E2 vaginal pessary, and prostaglandin E2 intracervical gel. Aust N Z J Obstet Gynaecol 1996; 36:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/53\">",
"      Atad J, Hallak M, Ben-David Y, et al. Ripening and dilatation of the unfavourable cervix for induction of labour by a double balloon device: experience with 250 cases. Br J Obstet Gynaecol 1997; 104:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/54\">",
"      Guinn DA, Davies JK, Jones RO, et al. Labor induction in women with an unfavorable Bishop score: randomized controlled trial of intrauterine Foley catheter with concurrent oxytocin infusion versus Foley catheter with extra-amniotic saline infusion with concurrent oxytocin infusion. Am J Obstet Gynecol 2004; 191:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/55\">",
"      Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. Obstet Gynecol 2006; 107:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/56\">",
"      Lin MG, Reid KJ, Treaster MR, et al. Transcervical Foley catheter with and without extraamniotic saline infusion for labor induction: a randomized controlled trial. Obstet Gynecol 2007; 110:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/57\">",
"      Gilson GJ, Russell DJ, Izquierdo LA, et al. A prospective randomized evaluation of a hygroscopic cervical dilator, Dilapan, in the preinduction ripening of patients undergoing induction of labor. Am J Obstet Gynecol 1996; 175:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/58\">",
"      Chua S, Arulkumaran S, Vanaja K, Ratnam SS. Preinduction cervical ripening: prostaglandin E2 gel vs hygroscopic mechanical dilator. J Obstet Gynaecol Res 1997; 23:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/59\">",
"      Krammer J, Williams MC, Sawai SK, O'Brien WF. Pre-induction cervical ripening: a randomized comparison of two methods. Obstet Gynecol 1995; 85:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/60\">",
"      Weiss G, Teichman S, Stewart D, et al. A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies. Ann N Y Acad Sci 2009; 1160:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/61\">",
"      Bell RJ, Permezel M, MacLennan A, et al. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening. Obstet Gynecol 1993; 82:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/62\">",
"      Brennand JE, Calder AA, Leitch CR, et al. Recombinant human relaxin as a cervical ripening agent. Br J Obstet Gynaecol 1997; 104:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/63\">",
"      Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992; 80:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/64\">",
"      Giacalone PL, Targosz V, Laffargue F, et al. Cervical ripening with mifepristone before labor induction: a randomized study. Obstet Gynecol 1998; 92:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/65\">",
"      Wing DA, Fassett MJ, Mishell DR. Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet Gynecol 2000; 96:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/66\">",
"      Stenlund PM, Ekman G, Aedo AR, Bygdeman M. Induction of labor with mifepristone--a randomized, double-blind study versus placebo. Acta Obstet Gynecol Scand 1999; 78:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/67\">",
"      Elliott CL, Brennand JE, Calder AA. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet Gynecol 1998; 92:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/68\">",
"      Su H, Li E, Weng L. [Mifepristone for induction of labor]. Zhonghua Fu Chan Ke Za Zhi 1996; 31:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/69\">",
"      Lelaidier C, Baton C, Benifla JL, et al. Mifepristone for labour induction after previous caesarean section. Br J Obstet Gynaecol 1994; 101:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/70\">",
"      Berkane N, Verstraete L, Uzan S, et al. Use of mifepristone to ripen the cervix and induce labor in term pregnancies. Am J Obstet Gynecol 2005; 192:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/71\">",
"      Wing DA, Guberman C, Fassett M. A randomized comparison of oral mifepristone to intravenous oxytocin for labor induction in women with prelabor rupture of membranes beyond 36 weeks' gestation. Am J Obstet Gynecol 2005; 192:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/72\">",
"      Kelly AJ, Munson C, Minden L. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev 2011; :CD006901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/73\">",
"      Kavanagh J, Kelly AJ, Thomas J. Hyaluronidase for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/74\">",
"      Kavanagh J, Kelly AJ, Thomas J. Corticosteroids for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/75\">",
"      Kelly AJ, Kavanagh J, Thomas J. Castor oil, bath and/or enema for cervical priming and induction of labour. Cochrane Database Syst Rev 2001; :CD003099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/76\">",
"      Kavanagh J, Kelly AJ, Thomas J. Sexual intercourse for cervical ripening and induction of labour. Cochrane Database Syst Rev 2001; :CD003093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/77\">",
"      Omar NS, Tan PC, Sabir N, et al. Coitus to expedite the onset of labour: a randomised trial. BJOG 2013; 120:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/78\">",
"      Kavanagh J, Kelly AJ, Thomas J. Breast stimulation for cervical ripening and induction of labour. Cochrane Database Syst Rev 2005; :CD003392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/79\">",
"      McFarlin BL, Gibson MH, O'Rear J, Harman P. A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice. J Nurse Midwifery 1999; 44:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/0/41993/abstract/80\">",
"      Dowswell T, Kelly AJ, Livio S, et al. Different methods for the induction of labour in outpatient settings. Cochrane Database Syst Rev 2010; :CD007701.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5398 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41993=[""].join("\n");
var outline_f41_0_41993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS OF AVAILABLE DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92003895\">",
"      PROSTAGLANDINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2274813\">",
"      Evidence of efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5354331\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2276848\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2277345\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92003902\">",
"      Prostaglandin E2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2274829\">",
"      - Prepidil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2274844\">",
"      - Cervidil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92003909\">",
"      Prostaglandin E1 (misoprostol)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92003916\">",
"      - Vaginal administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2276838\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92003930\">",
"      - Oral administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2276919\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92003937\">",
"      - Buccal or sublingual administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194729129\">",
"      - Combination therapy with mechanical methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANICAL METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Balloon catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277222\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13846255\">",
"      Foley catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13846262\">",
"      Double balloon catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277229\">",
"      - Evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277316\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277400\">",
"      - Balloon catheter combined with uterotonic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Catheter and infusion of extra-amniotic saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hygroscopic dilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277617\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2277624\">",
"      - Evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2278937\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13846292\">",
"      FETAL DEMISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTPATIENT CERVICAL RIPENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20153268\">",
"      Unfavorable cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Favorable cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5398|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/60/40896\" title=\"figure 1\">",
"      Cervical remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/16/7438\" title=\"figure 2\">",
"      Misoprostol lvls oral v vaginal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/19/19770\" title=\"figure 3\">",
"      Cervical ripening balloon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/41/27291\" title=\"table 1\">",
"      The modified Bishop score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/46/4843\" title=\"table 2\">",
"      C-S rate by Bishop score no PG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=related_link\">",
"      Cervical ripening and induction of labor in women with a prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_0_41994="Pemphigus vulgaris large erosions";
var content_f41_0_41994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63170%7EDERM%2F53425%7EDERM%2F57924%7EDERM%2F77462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63170%7EDERM%2F53425%7EDERM%2F57924%7EDERM%2F77462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions on the trunk skin of this patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flaccid bullae and erosions on the skin of a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris - oral lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions on the&nbsp;palate in a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions on the tongue and lips are present in this patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41994=[""].join("\n");
var outline_f41_0_41994=null;
var title_f41_0_41995="Major causes of hypoaldosteronism";
var content_f41_0_41995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypoaldosteronism (type 4 RTA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduced aldosterone production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hyporeninemic hypoaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal disease, most often diabetic nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonsteroidal anti-inflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calcineurin inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Volume expansion, as in acute glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin inhibitors, such as ACE inhibitors, angiotensin II receptor blockers, and direct renin inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inherited disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital isolated hypoaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudohypoaldosteronism type 2 (Gordon's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Aldosterone resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inhibition of the epithelial sodium channel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Potassium-sparing diuretics, such as spironolactone, eplerenone, amiloride, and triamterine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antibiotics, trimethoprim and pentamidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudohypoaldosteronism type 1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41995=[""].join("\n");
var outline_f41_0_41995=null;
var title_f41_0_41996="Warfarin interactions PI";
var content_f41_0_41996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that interfere with the effect of warfarin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Increased warfarin effect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetaminophen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Allopurinol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anabolic steroids",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aspirin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Capecitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cephalosporins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ciprofloxacin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clofibrate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clopidogrel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diclofenac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Disulfiram",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Erythromycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluconazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorouracil (5-FU)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Selective serotonin reuptake inhibitors (eg, Fluoxetine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glucagon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Influenza virus vaccine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metronidazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Macrolide antibiotics",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Omeprazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfamethoxazole/trimethoprim",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tamoxifen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thyroid hormone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolbutamide",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Decreased warfarin effect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Azathioprine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antithyroid drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbamazepine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dicloxacillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glutethimide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Griseofulvin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Haloperidol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nafcillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oral contraceptives",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rifampin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vitamin K",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     This is only a",
"     <strong>",
"      partial list",
"     </strong>",
"     . Please refer to the warfarin drug information topic for additional drug interactions. Some drugs may have multiple, opposing effects on warfarin; in such cases, the drug may increase or decrease the effect of warfarin, depending on which aspect of the drug interaction is dominant in that particular patient.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41996=[""].join("\n");
var outline_f41_0_41996=null;
var title_f41_0_41997="Suspected PE in pregnancy";
var content_f41_0_41997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for suspected pulmonary embolism in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PE: pulmonary embolism; CUS: compression ultrasound; CXR: chest radiography; CTPA: computed-tomographic pulmonary angiography; V/Q: ventilation-perfusion.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission of the American Thoracic Society. Copyright &copy; 2011 American Thoracic Society. Leung AN, Bull TM, Jaeschke R, et al. An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism In Pregnancy. Am J Respir Crit Care Med 2011; 184:1200. Official Journal of the American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41997=[""].join("\n");
var outline_f41_0_41997=null;
var title_f41_0_41998="Gram stain urine 2";
var content_f41_0_41998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain urine 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41998=[""].join("\n");
var outline_f41_0_41998=null;
var title_f41_0_41999="Granular cell tumor";
var content_f41_0_41999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Granular cell tumor in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Endoscopic image of a subepithelial 3.5 cm esophageal mass later shown to be a granular cell tumor. B) Endosonographic image revealing a hypoechoic mass arising from the submucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_0_41999=[""].join("\n");
var outline_f41_0_41999=null;
